DE102009029423A1 - Antibacterial cosmetic or pharmaceutical body odor deodorant compositions against body odor - Google Patents

Abstract

Certain bacteriophages are suitable for incorporation into certain antiperspirant and deodorant compositions and there effectively and specifically control the odor-causing bacteria without irritating the skin or damaging the main positive germs in the skin flora. Corresponding cosmetic or pharmaceutical compositions suitable for body deodorization contain in a cosmetically or dermatologically compatible carrier at least one deodorant or antiperspirant active ingredient and at least one representative from the group of bacteriophages which are effective at least one of the following: Staphylococcus aureus and / or Staphylococcus hominis and / or Corynebacterium tuberculostearicum and / or Anaerococcus octavius and / or Staphylococcus. Lugdunensis and / or Finegoldia magna and / or Corynebacterium amycolatum and / or Corynebacterium afermentans and / or Staphylococcus epidermidis and / or Staphylococcus capitis and / or Staphylococcus haemolyticus and / or Propionibacterium avidophii and / or Corynebium and / or Porynebium and / or Corynebacterium and / or Porynebium

Description

The present application relates to cosmetic or pharmaceutical compositions suitable for body deodorization which have an improved action.

Commercially available antiperspirant compositions, hereinafter also referred to as antiperspirants, contain as antiperspirant active ingredient at least one water-soluble astringent inorganic and organic salts of aluminum, zinc or selected aluminum-zirconium mixed salts. Commercially available deodorant compositions, also referred to below as deodorants, often contain at least one antibacterial active ingredient as the deodorant active ingredient.

The antiperspirant active ingredients have no direct influence on the activity of the sweat glands, but minimize the narrowing of the discharge channels sweat secretion. The Al salts cause sweat inhibition on the treated skin surfaces by superficial blockage of the sweat gland ducts as a result of Al-mucopolysaccharide precipitation.

Antiperspirant and deodorant compositions are usually applied and applied in the forearm region or in the region of the armpits. The skin in this area is usually more sensitive than the rest of the body's skin, often at least as sensitive as the skin on the face. There is therefore a constant need for particularly skin-compatible formulations which are suitable as carriers for cosmetic and dermatological antiperspirant and deodorant compositions. Furthermore, there is a need for particularly skin-friendly formulations which, as carriers for cosmetic and dermatological antiperspirant and deodorant compositions, may be able to make the antiperspirant and deodorant active ingredients, which irritate the skin irritating occasionally, more skin-friendly or to reduce their irritative effect ,

The object of the present invention was to find active substances and / or carriers for cosmetic and dermatological antiperspirant and deodorant compositions with particularly high skin tolerance. A further object of the present invention was to find active substances and / or carriers for cosmetic and dermatological antiperspirant and deodorant compositions which effectively and specifically combat the odor-causing bacteria without causing damage to the skin-positive bacteria in the skin flora.

The international patent application WO2009 / 101615 A1 proposes a method for reducing body odor in which an effective amount of a lytic bacteriophage capable of killing body odor causing bacteria is applied to the body surface. The document also discloses deodorant compositions containing bacteriophages as the active ingredient. About exact compositions makes the font but no information.

It has now been found that certain bacteriophages are eminently suitable for incorporation into certain antiperspirant and deodorant compositions where they effectively and specifically combat the odor-causing bacteria without irritating the skin or damaging the skin-positive bacteria in the skin flora.

• a) mindestens einen Deodorant- oder Antitranspirant-Wirkstoff,
• b) mindestens einen Vertreter aus der Gruppe der Bakteriophagen, die mindestens einen der folgenden Keime wirksam sind:
• b1) Staphylococcus aureus und/oder
• b2) Staphylococcus hominis und/oder
• b3) Corynebakterium tuberculostearicum und/oder
• b4) Anaerococcus octavius. und/oder
• b5) Staphylococcus. Lugdunensis und/oder
• b6) Finegoldia magna und/oder
• b7) Corynebacterium amycolatum und/oder
• b8) Corynebacterium afermentans und/oder
• b9) Staphylococcus epidermidis und/oder
• b10) Staphylococcus capitis und/oder
• b11) Staphylococcus haemolyticus und/oder
• b12) Propionibacterium avidum und/oder
• b13) Corynebacterium kroppenstedtii und/oder
• b14) Peptinophilus spec.

enthält.The present invention in a first embodiment is a cosmetic or pharmaceutical composition suitable for body deodorization, which is in a cosmetically or dermatologically acceptable carrier

• a) at least one deodorant or antiperspirant active ingredient,
• (b) at least one member of the group of bacteriophages which is active in at least one of the following micro-organisms:
• b1) Staphylococcus aureus and / or
• b2) Staphylococcus hominis and / or
• b3) Corynebacterium tuberculostearicum and / or
• b4) Anaerococcus octavius. and or
• b5) Staphylococcus. Lugdunensis and / or
• b6) Finegoldia magna and / or
• b7) Corynebacterium amycolatum and / or
• b8) Corynebacterium afermentans and / or
• b9) Staphylococcus epidermidis and / or
• b10) Staphylococcus capitis and / or
• b11) Staphylococcus haemolyticus and / or
• b12) Propionibacterium avidum and / or
• b13) Corynebacterium kroppenstedtii and / or
• b14) Peptinophilus spec.

contains.

Bacteriophages (or phages for short, from Greek phagein: eat) are a group of viruses that specialize in bacteria as host cells. This host specificity is consulted in the taxonomic classification of the phages.

Bacteriophages are taxonomically classified according to their morphology, genome and host. A distinction is made between DNA phages with single-stranded DNA, so-called single-stranded DNA phages (DNA) and double-stranded DNA, so-called ds-DNA phages (double-stranded DNA).

The so-called T-phages are distinguished from other bacteriophages by a relatively complex structure. Basically, they are composed of a base plate, an injection apparatus and a head consisting of the so-called capsid and the nucleic acid contained therein. The baseplate (which, like capsid and injection device, is made up of proteins) is studded with tail fibers and spikes that serve for adsorption on the host cell wall. The injection apparatus consists of a thin tube, also called tail tube, through which the phage DNA is injected into the host cell. The tube is surrounded by a contractile tail sheath, which contracts during the injection. The capsid is constructed with icosahedral symmetry of 152 capsomeres and contains the DNA of the phage. Due to this structure, the phages of the genus T4-like viruses are among the most structurally complex viruses.

By contrast, phages with single-stranded DNA are usually small, spherical and brushless or filamentous. The RNA phages, which also occur, usually consist of a protein shell that encloses a single-stranded RNA molecule. The diameter of these phages is about 25 nm, so they belong to the smallest phages.

Bacteriophages are found in the system of the virus taxonomy in the following taxonomic groups: dsDNA bacteriophages (families: Myoviridae, Siphoviridae, Podoviridae, Tectiviridae, Corticoviridae, Plasmaviridae, Podoviridae, Lipothrixvridae, Rudiviridae, Fusellovridae), genus Salterprovirus or family: Guttaviridae), ssDNA bacteriophages (families: Inoviridae, Microviridae), dsRNA bacteriophages (family: Cystoviridae), ssRNA bacteriophages (family: Leviviridae).

In addition, phages can also be classified according to their mechanism of action. Lysogenic phages nest genetically in the genome of the bacterium, survive there as so-called prophage and are also propagated with the cell division of bacteria. At some point (eg due to influences such as UV radiation) the prophage is released again and then destroys the bacterium.

Cosmetic or pharmaceutical compositions suitable for body deodorization which are preferred according to the invention are characterized in that the representative (s) from the group of bacteriophages is / are selected from the group of lysogenic bacteriophages.

A lytic phage invades the cell, proliferates there and then kills the cell immediately so that all phages can be released again. These phages work immediately and not just in a few generations of bacteria.

Particularly preferred cosmetic or pharmaceutical compositions according to the invention which are suitable for body deodorization are therefore characterized in that the representative (s) from the group of bacteriophages is / are selected from the group of lytic bacteriophages.

It is possible according to the invention to use phages which are active against a large number of Gram-positive and Gram-negative bacteria. For example, the product "PyoPhage" from the company BioPharm-L from Georgia has proved to be suitable. These phages can also be used immobilized on polymer membranes or nylon particles.

As already mentioned, it is particularly preferred according to the invention to use lytic phages. Very particularly preferred compositions according to the invention which are suitable for body deodorization are cosmetic or pharmaceutical compositions which contain exclusively lytic bacteriophages effective against Staphylococcus aureus. Also very particularly preferred according to the invention cosmetic or pharmaceutical compositions suitable for body deodorization are characterized in that they contain exclusively lytic, against Staphylococcus hominis bacteriophages effective. Further very particularly preferred cosmetic or pharmaceutical compositions according to the invention suitable for body deodorization are characterized in that they contain exclusively lytic bacteriophages effective against Corynebacterium tuberculostearicum.

• – ausschließlich lytische, gegen Anaerococcus octavius wirksame Bakteriophagen enthalten oder
• – ausschließlich lytische, gegen Staphylococcus lugdunensis wirksame Bakteriophagen enthalten oder
• – ausschließlich lytische, gegen Finegoldia magna wirksame Bakteriophagen enthalten oder
• – ausschließlich lytische, gegen Corynebacterium amycolatum wirksame Bakteriophagen enthalten oder
• – ausschließlich lytische, gegen Corynebacterium afermentans wirksame Bakteriophagen enthalten oder
• – ausschließlich lytische, gegen Staphylococcus epidermidis wirksame Bakteriophagen enthalten oder
• – ausschließlich lytische, gegen Staphylococcus capitis wirksame Bakteriophagen enthalten oder
• – ausschließlich lytische, gegen Staphylococcus haemolyticus wirksame Bakteriophagen enthalten oder
• – ausschließlich lytische, gegen Propionibacterium avidum wirksame Bakteriophagen enthalten oder
• – ausschließlich lytische, gegen Corynebacterium kroppenstedtii wirksame Bakteriophagen enthalten oder
• – ausschließlich lytische, gegen Peptinophilus spec. wirksame Bakteriophagen enthalten.

Further very particularly preferred compositions according to the invention are characterized in that they

• Contain exclusively lytic bacteriophages active against Anaerococcus octavius or
• Contain exclusively lytic bacteriophages active against Staphylococcus lugdunensis, or
• Contain exclusively lytic bacteriophages effective against Finegoldia magna, or
• Contain exclusively lytic bacteriophages active against Corynebacterium amycolatum or
• Contain exclusively lytic bacteriophages active against Corynebacterium afermentans or
• Contain exclusively lytic bacteriophages active against Staphylococcus epidermidis or
• Contain exclusively lytic bacteriophages active against Staphylococcus capitis or
• Contain exclusively lytic bacteriophages active against Staphylococcus haemolyticus or
• Contain exclusively lytic bacteriophages active against Propionibacterium avidum or
• Contain exclusively lytic bacteriophages active against Corynebacterium kroppenstedtii or
• - exclusively lytic, against Peptinophilus spec. contain effective bacteriophages.

Regardless of which bacteriophage (s) are included in the compositions of the present invention, preferred are cosmetic or pharmaceutical compositions suitable for body deodorization which are 10 ¹ -10 ^9, preferably 10 ² to 10 ⁸ , more preferably 10 ³ to 10 ⁷ , more preferably 10 ⁴ to 10 ⁶ wt .-%, and in particular 10 ⁴ to 10 ⁵ bacteriophages contain.

The compositions according to the invention can be formulated in various forms, for example as (optionally oil and fat-free) gel, as cream, in stick form, as a liquid or gel roll on application, as impregnated flexible substrate (pad), but also as powder or Spray.

Compositions of the invention may be in solid, semi-solid, liquid, disperse, emulsified, suspended or gel form. Furthermore, the agents according to the invention can be formulated as an aerosol, that is, they are packaged in a pressure vessel, from which they can be sprayed with the aid of a propellant. Furthermore, the agents according to the invention can be sprayed as a propellant-free pump spray.

Depending on the dosage form, the compositions according to the invention contain further active ingredients and / or adjuvants.

Irrespective of their dosage form, the agents according to the invention contain at least one deodorant or antiperspirant active ingredient in addition to bacteriophage (s).

Preferred antiperspirant active ingredients are selected from the water-soluble astringent inorganic and organic salts of aluminum, zirconium and zinc or any desired mixtures of these salts.

According to the invention, water solubility is understood as meaning a solubility of at least 5% by weight at 20 ° C., that is to say amounts of at least 5 g of the antiperspirant active are soluble in 95 g of water at 20 ° C.

Particularly preferred antiperspirant active ingredients are selected from aluminum chlorohydrate, in particular aluminum chlorohydrate having the general formula [Al ₂ (OH) ₅ Cl. 1-6H ₂ O] _n , preferably [Al ₂ (OH) ₅ Cl. 2-3H ₂ O] _n , which may be in unactivated or activated (depolymerized) form, and aluminum chlorohydrate of the general formula [Al ₂ (OH) ₄ Cl ₂ .1-6H ₂ O] _n , preferably [Al ₂ (OH) ₄ Cl ₂ 2-3H ₂ O] _n , which may be in unactivated or activated (depolymerized) form.

The preparation of preferred antiperspirant active ingredients is for example in US 3887692 . US 3904741 . US 4359456 . GB 2048229 and GB 1347950 disclosed.

Also preferred are aluminum sesquichlorohydrate, aluminum dichlorohydrate, aluminum chlorohydrex-propylene glycol (PG) or aluminum chlorohydrex-polyethylene glycol (PEG), aluminum or aluminum zirconium glycol complexes, e.g. Aluminum or aluminum zirconium-propylene glycol complexes, aluminum sesquichlorohydrex PG or aluminum sesquichlorohydrex PEG, aluminum PG dichlorohydrex or aluminum PEG dichlorohydrex, aluminum hydroxide further selected from the aluminum zirconium chlorohydrates such as aluminum zirconium trichlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium pentachlorohydrate, aluminum zirconium octachlorohydrate, aluminum zirconium chlorohydrate glycine complexes, such as Aluminiumzirconiumtrichlorohydrexglycin, Aluminiumzirconiumtetrachlorohydrexglycin, Aluminiumzirconiumpentachlorohydrexglycin, Aluminiumzirconiumoctachlorohydrexglycin, potassium aluminum sulphate (KAl (SO _{4) 2} · 12H ₂ O, alum), Aluminiumundecylenoylcollagenaminosäure, Natriumaluminiumlactat + aluminum sulfate, sodium aluminum, aluminum bromohydrate, aluminum chloride, complexes of zinc and sodium salts, the complexes of lanthanum and cerium, the aluminum salts of lipoamino acids, aluminum sulfate, Aluminum lactate, aluminum chlorohydrate, sodium zinc chlorohydroxactate, zinc chloride, zinc sulfocarbolate, zinc sulfate, zirconyl oxyhalides, especially zirconyl oxychlorides, zirconyl hydroxy halides, especially zirconyl chlorohydrate.

Antiperspirant active ingredients which are particularly preferred according to the invention are selected from what are known as "activated" aluminum and aluminum zirconium salts, which are also referred to as "enhanced activity" as antiperspirant active ingredients. Such agents are known in the art and are also commercially available. Their production is for example in GB 2048229 . US 4775528 and US 6010688 disclosed. Activated aluminum and aluminum zirconium salts are usually through Heat treatment of a relatively dilute solution of the salt (e.g., about 10% by weight salt) to increase its HPLC peak 4-to-peak 3 area ratio. The activated salt can then be dried to a powder, in particular spray-dried. In addition to the spray drying z. B. also suitable for drum drying.

Activated aluminum and aluminum zirconium salts typically have a HPLC peak 4-to-peak 3 area ratio of at least 0.4, preferably at least 0.7, more preferably at least 0.9, with at least 70% of the aluminum attributable to these peaks ,

Activated aluminum and aluminum zirconium salts do not necessarily have to be used as a spray-dried powder. Antiperspirant active ingredients which are likewise preferred according to the invention are nonaqueous solutions or solubilisates of an activated antiperspirant aluminum or aluminum zirconium salt, for example according to US 6010688 characterized by the addition of an effective amount of a polyhydric alcohol having from 3 to 6 carbon atoms and from 3 to 6 hydroxyl groups, preferably propylene glycol, sorbitol and pentaerythritol, against the loss of activation against the rapid degradation of the HPLC peak 4: peak 3-area ratio of the salt are stabilized. For example, preferred are compositions containing by weight (USP): 18-45% by weight of an activated aluminum or aluminum zirconium salt, 55-82% by weight of at least one anhydrous polyhydric alcohol of 3 to 6 carbon atoms and 3 to 6 Hydroxyl groups, preferably propylene glycol, butylene glycol, diethylene glycol, dipropylene glycol, glycerol, sorbitol and pentaerythritol, more preferably propylene glycol. Also particularly preferred are complexes of activated antiperspirant aluminum or aluminum-zirconium salts with a polyhydric alcohol containing 20-50% by weight, more preferably 20-42% by weight, activated antiperspirant aluminum or aluminum zirconium salt and 2-16% by weight % molecularly bound water, the remainder to 100 wt .-% is at least one polyhydric alcohol having 3 to 6 carbon atoms and 3 to 6 hydroxyl groups. Propylene glycol, propylene glycol / sorbitol mixtures and propylene glycol / pentaerythritol mixtures are preferred such alcohols. Such inventively preferred complexes of an activated antiperspirant aluminum or aluminum zirconium salt with a polyhydric alcohol are, for. B. disclosed in US 5643558 and US 6245325 , Further preferred antiperspirant active ingredients are basic calcium aluminum salts, as used, for example, in US Pat US 2571030 are disclosed. These salts are prepared by reacting calcium carbonate with aluminum chlorhydroxide or aluminum chloride and aluminum powder or by adding calcium chloride dihydrate to aluminum chlorhydroxide.

Further preferred antiperspirant active compounds are aluminum-zirconium complexes, as described, for example, in US Pat US 4017599 are disclosed, which are buffered with salts of amino acids, in particular with alkali and Erdalkaliglycinaten.

Other preferred antiperspirant actives are activated aluminum or aluminum-zirconium salts, as described, for example, in US Pat US 6245325 or US 6042816 containing 5-78% by weight (USP) of an activated antiperspirant aluminum or aluminum zirconium salt, an amino acid or hydroxyalkanoic acid in such an amount to give an (amino acid or hydroxyalkanoic acid) (Al + Zr) weight ratio of 2 : 1-1: 20 and preferably 1: 1 to 1:10, and a water-soluble calcium salt in such an amount to have a Ca: (Al + Zr) weight ratio of 1: 1 to 1:28 and preferably 1: 2 -1: 25 provide.

Particularly preferred solid activated antiperspirant salt compositions, for example according to US 6245325 or US 6042816 containing 48-78 wt .-% (USP), preferably 66-75 wt .-% of an activated aluminum or aluminum zirconium salt and 1-16 wt .-%, preferably 4-13 wt .-% molecularly bound water ( Water of hydration), further enough water-soluble calcium salt, that the Ca: (Al + Zr) weight ratio is 1: 1-1: 28, preferably 1: 2-1: 25, and so much amino acid that the amino acid becomes (Al + Zr) Weight ratio 2: 1-1: 20, preferably 1: 1-1: 10.

Further particularly preferred solid antiperspirant activated salt compositions, for example according to US 6245325 or US 6042816 containing 48-78 wt .-% (USP), preferably 66-75 wt .-% of an activated aluminum or aluminum zirconium salt and 1-16 wt .-%, preferably 4-13 wt .-% molecularly bound water ( Water of hydration), further enough water-soluble calcium salt, that the Ca: (Al + Zr) weight ratio is 1: 1-1: 28, preferably 1: 2-1: 25, and enough glycine that the glycine is (Al + Zr) Weight ratio 2: 1-1: 20, preferably 1: 1-1: 10.

Further particularly preferred solid antiperspirant activated salt compositions, for example according to US 6245325 or US 6042816 containing 48-78% by weight (USP), preferably 66-75% by weight of an activated aluminum or aluminum-zirconium salt and 1-16% by weight, preferably 4-13% by weight of molecularly bound water, further enough so much water-soluble calcium salt that the Ca: (Al + Zr) weight ratio is 1: 1-1: 28, preferably 1: 2-1: 25, and so much Hydroxyalkanoic acid that the hydroxyalkanoic acid is to (Al + Zr) weight ratio 2: 1-1: 20, preferably 1: 1-1: 10.

Preferred water-soluble calcium salts for the stabilization of antiperspirant salts are selected from calcium chloride, calcium bromide, calcium nitrate, calcium citrate, calcium formate, calcium acetate, calcium gluconate, calcium ascorbate, calcium lactate, calcium glycinate, calcium carbonate, calcium sulfate, calcium hydroxide, and mixtures thereof.

Preferred amino acids for the stabilization of the antiperspirant salts are selected from glycine, alanine, leucine, isoleucine, β-alanine, valine, cysteine, serine, tryptophan, phenylalanine, methionine, β-amino-n-butanoic acid and γ-amino-n-butanoic acid and the salts thereof, each in the d-form, the l-form and the dl-form; Glycine is particularly preferred.

Preferred hydroxyalkanoic acids for the stabilization of the antiperspirant salts are selected from glycolic acid and lactic acid.

Other preferred antiperspirant actives are activated aluminum or aluminum-zirconium salts, as described, for example, in US Pat US 6902723 containing 5-78% by weight (USP) of an activated antiperspirant aluminum or aluminum zirconium salt, an amino acid or hydroxyalkanoic acid in such an amount to give an (amino acid or hydroxyalkanoic acid) (Al + Zr) weight ratio of 2 : 1-1: 20 and preferably 1: 1 to 1:10, and a water-soluble strontium salt in such an amount to have a Sr: (Al + Zr) weight ratio of 1: 1-1: 28, and preferably 1: 2 -1: 25 provide.

Particularly preferred solid antiperspirant activated salt compositions, for example according to US 6902723 containing 48-78% by weight (USP), preferably 66-75% by weight of an activated aluminum or aluminum-zirconium salt and 1-16% by weight, preferably 4-13% by weight of molecularly bound water, further, enough water-soluble strontium salt that the Sr: (Al + Zr) weight ratio is 1: 1-1: 28, preferably 1: 2-1: 25, and so much amino acid that the amino acid becomes (Al + Zr) weight ratio 2 : 1-1: 20, preferably 1: 1-1: 10.

Further particularly preferred solid antiperspirant activated salt compositions, for example according to US 6902723 containing 48-78% by weight (USP), preferably 66-75% by weight of an activated aluminum or aluminum-zirconium salt and 1-16% by weight, preferably 4-13% by weight of molecularly bound water, further, enough water-soluble strontium salt that the Sr: (Al + Zr) weight ratio is 1: 1-1: 28, preferably 1: 2-1: 25, and enough glycine that the glycine would become (Al + Zr) weight ratio 2 : 1-1: 20, preferably 1: 1-1: 10.

Further particularly preferred solid antiperspirant activated salt compositions, for example according to US 6902723 containing 48-78% by weight (USP), preferably 66-75% by weight of an activated aluminum or aluminum-zirconium salt and 1-16% by weight, preferably 4-13% by weight of molecularly bound water, further enough so much water-soluble strontium salt that the Sr: (Al + Zr) weight ratio is 1: 1-1: 28, preferably 1: 2-1: 25, and enough hydroxyalkanoic acid that the hydroxyalkanoic acid becomes (Al + Zr) weight ratio 2 : 1-1: 20, preferably 1: 1-1: 10.

Further preferred activated aluminum salts are those of the general formula Al ₂ (OH) _6-a Xa in which X is Cl, Br, I or NO ₃ and "a" is a value of 0.3 to 5, preferably of 0.8 to 2 , 5 and more preferably 1 to 2, such that the molar ratio of Al: X is 0.9: 1 to 2.1: 1, as described, for example, in U.S. Pat US 6074632 are disclosed. These salts generally associate some hydration water, typically 1 to 6 moles of water per mole of salt. Particularly preferred is aluminum chlorohydrate (ie, X is Cl in the aforementioned formula) and especially 5/6 basic aluminum chlorohydrate wherein "a" is 1 such that the molar ratio of aluminum to chlorine is 1.9: 1 to 2.1: 1 ,

Preferred activated aluminum-zirconium salts are those which are mixtures or complexes of the aluminum salts described above with zirconium salts of the formula ZrO (OH) _2-pb Y _b represent wherein Y is Cl, Br, I, NO ₃ or SO _4, b is a rational number from 0.8 to 2 and p is the valence of Y, as described, for example, in US 6074632 are disclosed. The zirconium salts also typically associate some hydration water associatively, typically 1 to 7 moles of water per mole of salt. Preferably, the zirconium salt is zirconyl hydroxychloride of the formula ZrO (OH) _2-b Cl _b , wherein b is a rational number of from 0.8 to 2, preferably from 1.0 to 1.9. Preferred aluminum-zirconium salts have a molar Al: Zr molar ratio of 2 to 10 and a metal: (X + Y) ratio of 0.73 to 2.1, preferably 0.9 to 1.5. A particularly preferred salt is aluminum-zirconium chlorohydrate (ie, X and Y are Cl), which has a molar Al: Zr ratio of 2 to 10 and a molar metal: Cl ratio of 0.9 to 2.1. The term aluminum-zirconium chlorohydrate includes the tri-, tetra-, penta- and octachlorohydrate forms.

Zirconium salts preferred according to the invention have the general formula ZrO (OH) _2-a Cl _a .xH ₂ O where a = 1.5-1.87; x = 1-7, where a and x are rational Numbers are. These zirconium salts are, for example, in the Belgian script BE 825146 disclosed.

Further preferred antiperspirant active substances are in US 6663854 and US 20040009133 disclosed. The antiperspirant active ingredients can be present both in solubilized and in undissolved, suspended form.

If the antiperspirant active ingredients are suspended in a water-immiscible carrier, it is preferred for reasons of product stability that the active ingredient particles have a number-average particle size of 0.1-200 .mu.m, preferably 1-50 .mu.m, particularly preferably 3-20 .mu.m and extraordinarily preferably 5-10 μm. Preferred active substance particles have a volume-average particle size of 0.2-220 .mu.m, preferably 3-60 .mu.m, more preferably 4-25 .mu.m and most preferably 10-15.5 .mu.m.

Preferred aluminum salts and aluminum zirconium salts have a molar metal-to-chloride ratio of 0.9-2.0, preferably 1.0-1.51, more preferably 1.1-1.5, most preferably 1.3-1, 4, up.

Preferred aluminum zirconium chlorohydrates have the empirical formula Al _n Zr (OH) _{[3n + 4-m (n + 1)]} (Cl) _{[m (n + 1)]} where n = 2.0-10.0, preferably 3.0 -8.0, m = 0.77-1.11 (corresponding to a molar metal (Al + Zr) to chloride ratio of 1.3-0.9), preferably m = 0.91-1.11 (corresponding to M: Cl = 1.1-0.9), and particularly preferably m = 1.00-1.11 (corresponding to M: Cl = 1.0-0.9), furthermore very preferably m = 1.02 -1.11 (corresponding to M: Cl = 0.98-0.9) and more preferably m = 1.04-1.11 (corresponding to M: Cl = 0.96-0.9).

Other preferred aluminum zirconium trichlorohydrates have the empirical formula Al ₄ (OH) ₁₀ Cl ₂ .Zr (OH) Cl.

Other preferred aluminum zirconium tetrachlorohydrates have the empirical formula Al ₄ (OH) ₁₀ Cl ₂ .ZrCl ₂ .

Further preferred aluminum zirconium pentachlorohydrates have the empirical formula Al ₈ (OH) ₂₀ Cl ₆ .Zr (OH) Cl.

Other preferred aluminum zirconium octachlorohydrates have the empirical formula Al ₈ (OH) ₁₈ Cl ₆ .Zr (OH) Cl.

In general, some of the water of hydration is associatively bound to these salts, typically 1-6 moles of water per mole of salt, corresponding to 1-30% by weight, preferably 4-13% by weight of hydration water. Preferred antiperspirant salts are aluminum zirconium tetrachlorohydrates (molar ratio Al: Zr = 2-6, M: Cl = 0.9-1.5, preferably 0.95: 1.3, more preferably 1.0: 1.1), in particular salts with one molar metal to chloride ratio of 0.9-1.1, preferably 0.9-1.0.

Other preferred antiperspirant salts are aluminum chlorohydrates having a molar metal to chloride ratio of M: Cl = 1.9-2.1.

Usually, the preferred aluminum zirconium chlorohydrates are associated with an amino acid to prevent polymerization of the zirconium species during manufacture. Preferred stabilizing amino acids are selected from glycine, alanine, leucine, isoleucine, β-alanine, cysteine, valine, serine, tryptophan, phenylalanine, methionine, β-amino-n-butanoic acid and γ-amino-n-butanoic acid and the salts thereof, each in the d-form, the l-form and the dl-form; Glycine is particularly preferred. The amino acid is contained in the salt in an amount of 1-3 moles, preferably 1.3-1.8 moles, per mole of zirconium. The aforementioned aluminum-zirconium trichlorohydrates, aluminum-zirconium tetrachlorohydrates, aluminum-zirconium pentachlorohydrates, and aluminum-zirconium octachlorohydrates are preferably present as complexed with glycine, both activated and unactivated.

Particularly preferred antiperspirant active ingredients are selected from activated aluminum-zirconium trichlorohydrex glycine, in particular activated aluminum-zirconium trichlorohydrex glycine with an anhydrous and glycine-free active substance (USP) of 69.5-88 wt .-%, preferably 72-85 wt .-%, particularly preferably 77-80 wt .-%, each based on the raw material tel quel, a molar metal: Cl ratio of 0.9 to 1.5 and a molar Al: Zr ratio of 3.4-3.8.

Other particularly preferred antiperspirant actives are selected from non-activated aluminum-zirconium trichlorohydrex glycine, especially non-activated aluminum-zirconium trichlorohydrex glycine with an anhydrous and glycine-free active substance (USP) of 69.5-88 wt%, preferably 72-85 Wt .-%, particularly preferably 77-80 wt .-%, each based on the raw material tel quel, a molar metal: Cl Ratio of 0.9 to 1.5 and a molar Al: Zr ratio of 3.4-3.8.

Further particularly preferred antiperspirant active ingredients are selected from activated aluminum-zirconium tetrachlorohydrex glycine, in particular activated aluminum-zirconium tetrachlorohydrex glycine with an anhydrous and glycine-free active substance (USP) of 72-88 wt .-%, preferably 77-85 wt .-%, respectively based on the raw material tel quel, a molar metal: Cl ratio of 0.9 to 1.5 and a molar Al: Zr ratio of 3.4-3.8.

Further particularly preferred antiperspirant active ingredients are selected from non-activated aluminum-zirconium tetrachlorohydrex glycine, in particular non-activated aluminum-zirconium tetrachlorohydrex glycine with an anhydrous and glycine-free active substance (USP) of 72-88 wt .-%, preferably 77-85 wt. -%, in each case based on the raw material tel quel, a molar metal: Cl ratio of 0.9 to 1.5 and a molar Al: Zr ratio of 3.4-3.8.

Further particularly preferred antiperspirant active ingredients are selected from activated aluminum-zirconium pentachlorohydrex glycine, in particular activated aluminum zirconium pentachlorohydrex glycine with an anhydrous and glycine-free active substance (USP) of 72-88 wt .-%, preferably 77-86 wt .-%, especially preferably 78-81.5 wt .-%, each based on the raw material tel quel, a molar metal: Cl ratio of 1.51 to 2.0 and a molar Al: Zr ratio of 9.2-9.8 ,

Further particularly preferred antiperspirant active ingredients are selected from non-activated aluminum zirconium pentachlorohydrex glycine, in particular non-activated aluminum zirconium pentachlorohydrex glycine with a crystal water-free and glycine-free active substance (USP) of 72-88 wt .-%, preferably 77-86 wt. -%, particularly preferably 78-81.5 wt .-%, each based on the raw material tel quel, a molar metal: Cl ratio of 1.51 to 2.0 and a molar Al: Zr ratio of 9.2 -9.8.

The water of crystallization content of the aforementioned activated as well as unactivated aluminum zirconium trichlorohydrex glycines, aluminum zirconium tetrachlorohydrex glycines, aluminum zirconium pentachlorohydrex glycines and aluminum zirconium octachlorohydrex glycines is 1.5-20% by weight, preferably 7-15% by weight, respectively based on the raw material tel quel.

Other preferred aluminum zirconium trichlorohydrex glycols have the empirical formula [Al ₄ (OH) ₁₀ Cl ₂ .Zr (OH) Cl] .NH ₂ CH ₂ COOH.

Further preferred aluminum zirconium tetrachlorohydrex glycines have the empirical formula [Al ₄ (OH) ₁₀ Cl ₂ .ZrOCl ₂ ] .NH ₂ CH ₂ COOH.

Other preferred aluminum zirconium pentachlorohydrex glycines have the empirical formula [Al ₈ (OH) ₂₀ Cl ₄ .Zr (OH) Cl] .NH ₂ CH ₂ COOH.

Other preferred aluminum-zirconium octachlorohydrex glycines have the empirical formula [Al ₈ (OH) ₁₈ Cl ₆ .Zr (OH) Cl] .NH ₂ CH ₂ COOH or [Al ₈ (OH) ₁₈ Cl ₆ .ZrOCl ₂ ] .NH ₂ CH ₂ COOH.

Also preferred according to the invention are aluminum zirconium chlorohydrate-glycine salts which are stabilized with betaine ((CH ₃ ) ₃ N ⁺ -CH ₂ -COO ^- ). Particularly preferred corresponding compounds have a total molar (betaine + glycine) / Zr ratio of (0.1-3.0): 1, preferably (0.7-1.5): 1, and a betaine molar ratio Glycine of at least 0.001: 1 on. Corresponding compounds are disclosed in, for example US 7105691 ,

In a particularly preferred embodiment according to the invention, the particularly effective antiperspirant salt comprises a so-called "activated" salt, in particular one with a high HPLC peak 5-aluminum content, in particular with a peak 5 surface of at least 33%, particularly preferred at least 45%, based on the total area under peaks 2-5, measured by HPLC of a 10% by weight aqueous solution of the active ingredient under conditions in which the aluminum species are resolved into at least 4 consecutive peaks (with peaks 5). Preferred aluminum zirconium salts having a high HPLC peak 5-aluminum content (also referred to as "E ⁵ AZCH") are disclosed, for example, in US Pat US 6436381 and US 6649152 ,

Furthermore, those activated "E ⁵ AZCH" salts whose HPLC peak has a 4-to-peak 3 area ratio of at least 0.4, preferably at least 0.7, particularly preferably at least 0.9, are preferred.

Further particularly preferred antiperspirant active ingredients are those aluminum zirconium salts having a high HPLC peak 5-aluminum content, which are additionally stabilized with a water-soluble strontium salt and / or with a water-soluble calcium salt. Corresponding salts are, for example, in US 6923952 disclosed.

Further preferred antiperspirant active ingredients are selected from astringent titanium salts, as used, for example, in US Pat GB 2299506 A are disclosed.

The antiperspirant active ingredients can be used as nonaqueous solutions or as glycolic solubilisates.

Particularly preferred compositions according to the invention are characterized in that the at least one antiperspirant active ingredient in an amount of 5-40 wt .-%, preferably 10-35 wt .-%, particularly preferably 11-28 wt .-% and most preferably 12-20% by weight, based on the total weight of the anhydrous and ligand-free active substance (USP) in the overall composition.

In a particularly preferred embodiment, the composition comprises an astringent aluminum salt, in particular aluminum chlorohydrate, particularly preferably aluminum chlorohydrate with an active substance (USP) free of water of crystallization of 72-88% by weight, based on the raw material tel quel. Preferred non-activated aluminum chlorohydrates, for example, in powder form as Micro Dry ^®, Micro Dry ^® Ultrafine or Micro Dry ^® -323 from Summit Reheis, as Chlorhydrol ^® (powder) as well as in activated form as Reach ^® 101, Reach ^® 103, Reach ^® 501 Reheis / Summit or AACH-7171 available from Summit. Under the name ^Reach® 301 an aluminum sesquichlorohydrate from Reheis is offered, which is likewise particularly preferred.

The use of aluminum-zirconium-tetrachlorohydrex-glycine complexes may also be particularly preferred according to the invention. Especially preferred are aluminum-zirconium tetrachlorohydrex-glycine complexes, for example, from Summit Reheis under the name Rezal ^® 36 GP, Summit AZG-369, or Summit AZG-364, or, in activated quality than Summit Reach ^® AZP-908 , as powders are on the market.

Also particularly preferred are aluminum-zirconium-pentachlorohydrex-glycine complexes, which are commercially available, for example, in activated quality from Summit under the designations AAZG-3108 and AAZG-3110.

The antiperspirant active ingredients are in the formulations of the invention in an amount of 1 to 40 wt .-%, preferably from 3 to 15 wt .-%, based on the total mass of the preparation, d. H. Including possibly existing propellants used.

In embroidery formulations, the proportion of antiperspirant active ingredients is preferably in the range from 10 to 25% by weight, in each case based on the total mass of the preparation.

Further particularly preferred stick compositions according to the invention are characterized in that the at least one antiperspirant active ingredient in an amount of 5-40 wt .-%, preferably 10-35 wt .-%, particularly preferably 11-28 wt .-% and most preferably 12 -20% by weight, based on the total weight of the water-free and ligand-free active substance (USP) in the total composition.

Particularly preferred spray compositions according to the invention are characterized in that the at least one antiperspirant active ingredient is present in an amount of 5-40% by weight, preferably 10-35% by weight, more preferably 11-28% by weight and most preferably 12- 20 wt .-%, based on the total weight of the water-free active substance (USP) in the blowing agent-free total composition.

Antiperspirant drugs from the groups of anticholinergics, such as 4 - [(2-cyclopentyl-2-hydroxyphenylacetyl) oxy] -1,1-dimethyl-piperidiniumsalze, in particular the 4 - [(2-cyclopentyl-2-hydroxyphenylacetyloxy] -1 , 1-Dimethyl-piperidinium bromide may be present in a proportion of preferably 0.05 to 1.0 wt .-%, preferably 0.1% -0.7%, in particular 0.3% -0.5 wt .-%, based be added to the total mass of the preparation.

Vicinal diols and similar active substances from the group of osmotically active substances can also be added as antiperspirant active ingredient to the preparations according to the invention, preferably to a proportion of 10 to 50% by weight, preferably 15% to 30%, in particular 15-25% by weight. -%, based on the total mass of the preparation.

In addition, of course, it is possible to add further antiperspirant active ingredients and / or deodorants.

Particularly preferred cosmetic or pharmaceutical compositions according to the invention which are suitable for body deodorization are characterized in that they contain at least one antiperspirant active ingredient in a total amount of 1-25% by weight, preferably 5-22% by weight and in particular 10-20% by weight. %, based on the total weight of the active substance in the whole composition. In a particularly preferred embodiment, the composition comprises an astringent aluminum salt, especially aluminum chlorohydrate, for example, in powder form as Micro Dry ^® Ultrafine from Reheis, in the form of an aqueous solution as Locron ^® L from Clariant, as Chlorhydrol ^® as well as in activated form as Reach ^® 501 Reheis is distributed. Under the name ^Reach® 301 an aluminum sesquichlorohydrate from Reheis is offered, which is likewise particularly preferred. The use of aluminum zirconium tetrachlorohydrex glycine complexes, which are, for example, by Reheis under the name Rezal ^® 36G commercially, may be particularly preferred according to the invention.

Very particularly preferred according to the invention are cosmetic or pharmaceutical composition suitable for body deodorization Accordingly, characterized in that they contain 3-25 wt .-%, preferably 5-22 wt .-% and in particular 10-20 wt .-% acidic aluminum and / or aluminum / zirconium salts, in particular cosmetic or pharmaceutical, for Körperdeodorierung suitable compositions are preferred which contain 3-25% by weight, preferably 5-22% by weight and in particular 10-20% by weight of activated aluminum chlorohydrate.

The compositions of the invention may additionally contain passivating agents. The passivating agents are preferably selected from the group of phyllosilicates and fillers, such as talc. Phyllosilicates are polymeric crystalline sodium disilicates. Phyllosilicates preferred according to the invention are selected from clay minerals, such as bentonite, montmorillonite, nontronite, hectorite, saponite, sauconite, beidellite, allevardite, illite, halloysite, attapulgite and / or sepiolite. Disteardimonium is hectorite. Hectorites are M0.3 + (Mg2.7Li0.3) [Si4O10 (OH) 2], M + mostly = Na +, the monmoclinic clay mineral belonging to the smectites and similar to montmorillonite.

Another passivating agent according to the invention is talc, talc or talcum, preferably talcum with the INCI name Talc, E553b. Talc is a natural, well-distributed magnesium silicate Mg3 [(OH) 2 / Si4O10] or 3MgO.4SiO2.H2O, which belongs to the three-layer (2: 1) phyllosilicates whose denser aggregates are called soapstone.

In summary, preferred cosmetic or pharmaceutical compositions suitable for body deodorization according to the invention are characterized in that they contain at least one passivating agent from the group of layered silicates and / or talc, preferred passivating agents being selected from the group of clay minerals, in particular selected from montmorillonite, nontronite, hectorite , Saponite, sauconite, beidellite, allevardite, illite, halloysite, attapulgite and / or sepiolite. Most preferred cosmetic or pharmaceutical body deodorizing compositions include disteardimonium hectorite as the passivating agent.

Deodorant active ingredients which are preferred according to the invention are odor absorbers, deodorizing ion exchangers, germ-inhibiting agents, prebiotic active components and also enzyme inhibitors or, particularly preferred, combinations of said active substances.

Preferred odor absorbers are, for example, zeolites, Zinkricinoleat, cyclodextrins, certain metal oxides, such as. As alumina, and chlorophyll. They are preferably used in an amount of 0.1-10% by weight, more preferably 0.5-7% by weight and most preferably 1-5% by weight, based in each case on the total composition.

According to the invention, germ-inhibiting or antimicrobial active ingredients are understood as meaning those active substances which reduce the number of skin germs participating in the formation of the odor or inhibit their growth. These organisms include, among others, various species from the group of staphylococci, the group of Corynebacteria, anaerococci and micrococci.

Preferred antimicrobial or antimicrobial agents according to the invention are in particular organohalogen compounds and halides, quaternary ammonium compounds, a number of plant extracts and zinc compounds. These include triclosan, chlorhexidine and chlorhexidine gluconate, 3,4,4'-trichlorocarbanilide, bromochlorophene, dichlorophen, chlorothymol, chloroxylenol, hexachlorophene, dichloro-m-xylenol, dequalinium chloride, domiphenbromide, ammonium phenolsulfonate, benzalkonium halides, benzalkonium cetyl phosphate, benzalkonium saccharinates, benzethonium chloride, cetylpyridinium chloride, Laurylpyridinium chloride, laurylisoquinolinium bromide, methylbenzethonium chloride. Furthermore, phenol, phenoxyethanol, disodium dihydroxyethylsulfosuccinylundecylenate, sodium bicarbonate, zinc lactate, sodium phenolsulfonate and zinc phenolsulfonate, ketoglutaric acid, terpene alcohols such as. As farnesol, chlorophyllin copper complexes, α-monoalkyl glycerol ether with a branched or linear saturated or unsaturated, optionally hydroxylated C ₆ -C ₂₂ alkyl, particularly preferably α- (2-ethylhexyl) glycerol ether, commercially available as Sensiva ^® SC 50 (ex Schülke & Mayr), carboxylic esters of mono-, di- and triglycerin (eg glycerol monolaurate, diglycerol monocaprinate), lantibiotics and plant extracts (eg green tea and components of lime blossom oil).

Further preferred deodorant active substances are selected from so-called prebiotic active components, which according to the invention are to be understood as meaning those components which inhibit only or at least predominantly the odor-causing germs of the skin microflora, but not the desired ones, that is to say the non-odor-causing germs belonging to a healthy skin microflora. Specifically included here are conifer extracts, especially from the group of Pinaceae, and plant extracts from the group of Sapindaceae, Araliaceae, Lamiaceae and Saxifragaceae, in particular extracts from Picea spp., Paullinia sp., Panax sp., Lamium album or Ribes nigrum and mixtures thereof substances.

Further preferred deodorant active ingredients are selected from the germ-inhibiting active perfume oils and Deosafe ^® -Parfümölen that, Haarmann and Reimer, by the company Symrise previously available. The enzyme inhibitors include substances which inhibit the enzymes responsible for the sweat decomposition, in particular arylsulfatase, β-glucuronidase, aminoacylase, esterases, lipases and / or lipoxigenase, e.g. B. trialkylcitric acid, in particular triethyl citrate, or zinc glycinate.

Preferred cosmetic or pharmaceutical body deodorizing compositions according to the invention are characterized in that the at least one deodorant active ingredient is selected from arylsulfatase inhibitors, β-glucuronidase inhibitors, aminoacylase inhibitors, esterase inhibitors, lipase inhibitors and lipoxigenase inhibitors, α-Monoalkylglycerinethern with a branched or linear saturated or unsaturated, optionally hydroxylated C ₆ -C ₂₂ alkyl radical, especially α- (2-ethylhexyl) glycerol ether, phenoxyethanol, germ inhibiting perfume oils, Deosafe ^® -Parfümölen (Deosafe ^® is a registered trademark of Company Symrise, formerly Haarmann & Reimer), prebiotic active compounds, trialkylcitric acid esters, in particular triethyl citrate, active substances which reduce the number of skin microorganisms involved in the formation of odor from the group of staphylococci, corynebacteria, anaerococci and micrococci or their Growth, zinc compounds, in particular zinc phenolsulfonate and zinc ricinoleate, organohalogen compounds, in particular triclosan, chlorhexidine, chlorhexidine gluconate and benzalkonium halides, quaternary ammonium compounds, in particular cetylpyridinium chloride, odor absorbers, in particular silicates and zeolites, sodium bicarbonate, lantibiotics, and mixtures of the abovementioned substances.

Further preferred cosmetic or pharmaceutical compositions of the invention suitable for body deodorization are characterized in that they contain 0.05-10% by weight, preferably 0.2-7% by weight, more preferably 0, based on the weight of the ready-to-use composition 3-5% by weight and most preferably 0.4-2.5% by weight of deodorant active ingredients in the overall composition.

Very particularly preferred compositions according to the invention which contain deodorant active ingredients are poor in or free from antiperspirant active substances. Preferred herein are cosmetic or pharmaceutical compositions suitable for body deodorization which are less than 5% by weight, preferably less than 2% by weight, more preferably less than 1% by weight, even more preferably less than 0.5% by weight .-% and in particular 0 wt .-% antiperspirant active ingredient (s) included.

As already mentioned, the compositions according to the invention can be formulated in various supply forms, for example as (optionally oil and fat-free) gel, as cream, in stick form, as liquid or gel roll on application, as impregnated flexible substrate (pad), but also as powder or spray. Compositions of the invention may be in solid, semi-solid, liquid, disperse, emulsified, suspended or gel form. Furthermore, the agents according to the invention can be formulated as an aerosol, that is, they are packaged in a pressure vessel, from which they can be sprayed with the aid of a propellant. Furthermore, the agents according to the invention can be sprayed as a propellant-free pump spray.

Preferred cosmetic or pharmaceutical compositions of the invention suitable for body deodorization are characterized in that they comprise a cosmetically or dermatologically acceptable carrier which can be in the form of powder, stick, aerosol spray, pump spray, liquid or gel roll-on application, cream, lotion, suspension , Solution, gel or applied to a substrate.

This carrier can be formulated water-based or low in water to anhydrous. Depending on the form of preparation, the carrier can also be formulated alcohol-based or low in alcohol to alcohol-free. A preferred embodiment of the present invention are cosmetic or pharmaceutical compositions suitable for body deodorization which, based on the weight of the ready-to-use composition, are 5-60% by weight, preferably 7.5-45% by weight, more preferably 10-40 Wt .-% and most preferably 15-35 wt .-% ethanol and / or isopropanol.

Another preferred embodiment of the present invention are cosmetic or pharmaceutical compositions suitable for body deodorization which are less than 5% by weight, preferably less than 2% by weight, more preferably less than 1% by weight, even more preferably less than 0.5 wt .-% and in particular 0 wt .-% ethanol and / or isopropanol.

The cosmetic and dermatological preparations according to the invention may contain cosmetic adjuvants such as are conventionally used in such preparations, eg. As preservatives, bactericides, UV filters, antioxidants, vitamins, minerals, suspended solid particles, perfumes, substances for preventing foaming, dyes, pigments, the one have coloring, thickening, moisturizing and / or moisturizing substances or other conventional ingredients of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers or silicone derivatives.

A further preferred embodiment of the invention is characterized in that the composition according to the invention or used according to the invention contains at least one monosaccharide having 5 or 6 carbon atoms and / or at least one disaccharide.

A particularly preferred embodiment of the invention is characterized in that the monosaccharide having 5 or 6 carbon atoms is selected from glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose, fucose and rhamnose , Exceptionally preferred are glucose, galactose, fructose, fucose and rhamnose, in particular glucose and galactose.

Another particularly preferred embodiment of the invention is characterized in that the disaccharide is selected from sucrose, lactose and trehalose. Exceptionally preferred are sucrose and lactose, especially lactose.

A further particularly preferred embodiment of the invention is characterized in that at least one monosaccharide having 5 or 6 carbon atoms and / or at least one disaccharide in a total amount of 0.001 to 2.0 wt .-%, preferably 0.005-1.0 wt .-% , Particularly preferably 0.01-0.5 wt .-% and most preferably 0.03-0.1 wt .-%, each based on the total composition is included.

If the compositions of the invention are in the form of a stick, they preferably contain a lipid or wax matrix comprising at least one lipid or wax component having a melting point in the range from 30 to 150 ° C, preferably in the range of> 50-120 ° C.

In general, waxes are of solid to brittle hard consistency, coarse to fine crystalline, translucent to opaque, but not glassy, and melt above 50 ° C without decomposition. They are already slightly above the melting point low viscosity and show a strong temperature-dependent consistency and solubility.

Further preferred compositions according to the invention, in particular those in the form of sticks and soft solids, are characterized in that they contain at least one fat component which is solid under normal conditions and has a melting point of more than 50-120 ° C.

Preferred fat components with a melting point of> 50-120 ° C are selected from waxes. In general, waxes are of solid to brittle hard consistency, coarse to fine crystalline, translucent to opaque, but not glassy, and melt above 50 ° C without decomposition. They are already slightly above the melting point low viscosity and show a strong temperature-dependent consistency and solubility.

Preference according to the invention, for example, natural vegetable waxes, z. Candelilla wax, carnauba wax, Japan wax, sugarcane wax, ouricoury wax, cork wax, sunflower wax, fruit waxes such as orange waxes, lemon waxes, grapefruit wax, and animal waxes, e.g. Beeswax, shellac wax and spermaceti. For the purposes of the invention, it may be particularly preferred to use hydrogenated or hardened waxes. As a wax component and chemically modified waxes, especially the hard waxes, such as. As montan ester waxes, hydrogenated jojoba waxes and Sasol waxes used. The synthetic waxes which are likewise preferred according to the invention include, for example, polyalkylene waxes, in particular polyethylene waxes, and polyethylene glycol waxes, C ₂₀ -C ₄₀ dialkyl esters of dimer acids, C _30-50 alkyl beeswax and alkyl and alkylaryl esters of dimer fatty acids. A particularly preferred wax component is selected from at least one ester of a saturated, monohydric C ₁₆ -C ₆₀ -alcohol and a saturated C ₈ -C ₃₆ -monocarboxylic acid. According to the invention, lactides, the cyclic double esters of α-hydroxycarboxylic acids of the corresponding chain length, also belong thereto. Esters of fatty acids and long-chain alcohols have proved to be particularly advantageous for the compositions preferred according to the invention because they provide excellent sensory properties and - the pins - a high stability. The esters are composed of saturated, branched or unbranched monocarboxylic acids and saturated, branched or unbranched monohydric alcohols. Also esters of aromatic carboxylic acids or hydroxycarboxylic acids (eg 12-hydroxystearic acid) and saturated, branched or unbranched alcohols can be used according to the invention, provided that the wax component has a melting point> 50 ° C. It is particularly preferred to choose the wax components from the group of esters of saturated, branched or unbranched alkanecarboxylic acids having a chain length of 12 to 24 carbon atoms and the saturated, branched or unbranched alcohols having a chain length of 16 to 50 carbon atoms, which has a melting point > 50 ° C.

In particular, C _{16-36 alkyl} stearates and C _18-38 alkyl hydroxystearoyl stearates, C _20-40 alkyl erucates and cetearyl behenate may be preferred as the wax component. The wax or the wax components have a melting point> 50 ° C, preferably> 60 ° C, on.

A particularly preferred embodiment of the invention contains as wax component a C ₂₀ -C ₄₀ alkyl stearate. This ester is known under the name Kester ^® K82H or Kesterwachs ^® K80H and is sold by Koster Keunen Inc.. It is the synthetic imitation of the monoester fraction of beeswax and is characterized by its hardness, oil gelability and broad compatibility with lipid components. Kester wax has the advantage that it has an excellent oil gelability even at low concentrations and so does not make the Stiff or Soft Solid mass too heavy and allows a velvety abrasion. A further particularly preferred embodiment of the invention contains as wax component cetearyl behenate, ie mixtures of cetyl behenate and stearyl behenate. This ester is known under the name Kester ^® K62 and is sold by Koster Keunen Inc..

Further preferred wax components having a melting point> 50 ° C are the triglycerides of saturated and optionally hydroxylated C _12-30 fatty acids, such as hardened triglyceride fats (hydrogenated palm oil, hydrogenated coconut oil, hydrogenated castor oil), glyceryl tribehenate (tribehenin) or glyceryl tri-12-hydroxystearate synthetic full esters of fatty acids and glycols or polyols having 2-6 carbon atoms, as long as they have a melting point above 50 ° C, for example preferably C ₁₈ -C ₃₆ Acid triglycerides (Syncrowax ^® HGL-C). According to the invention hydrogenated castor oil, obtainable, for example, as wax component is available. B. as a commercial product Cutina ^® HR, particularly preferred.

Further preferred lipid or wax components with a melting point> 50 ° C are the saturated linear C ₁₄ -C ₃₆ carboxylic acids, in particular myristic acid, palmitic acid, stearic acid and behenic acid and mixtures of these compounds, eg. B. Syncrowax ^® AW 1C (C ₁₈ -C ₃₆ fatty acids) or Cutina ^® FS 45 (palmitic and stearic acid).

Other preferred lipid or wax components having a melting point in the range of 30-150 ° C are linear, saturated C _8-30 fatty acids. Preferred are linear, saturated C _10-22 fatty acids. Preferred fatty acids are caproic, caprylic, 2-ethylhexanoic, capric, lauric, isotridecanoic, myristic, palmitic, palmitoleic, stearic, isostearic, oleic, elaidic, petroselic, elaeostearic, arachidonic, gadoleic, behenic and erucic acid, and technical mixtures thereof. Particularly preferred is the use of stearic acid. The fatty acids used can carry one or more hydroxyl groups. Preferred examples of these are the α-hydroxy-C ₈ -C ₁₈ -carboxylic acids and 12-hydroxystearic acid.

The amount used is preferably 0.1-10 wt .-%, particularly preferably 0.5-5 wt .-%, exceptionally preferably 1.5-3 wt .-%, each based on the total composition.

Other preferred lipid or wax components having a melting point in the range of 30-150 ° C are fatty alcohols. As fatty alcohols it is possible to use saturated, unbranched fatty alcohols having 6-30, preferably 10-22 and very particularly preferably 12-22 carbon atoms. Applicable for the purposes of the invention are z. For example, decanol, octanol, eruca alcohol, ricinoleic alcohol, 12-hydroxystearyl alcohol, stearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, capryl alcohol, capric alcohol and behenyl alcohol. Preferred stick compositions according to the invention are characterized in that the total amount of fatty alcohol having a melting point in the range of 30-150 ° C 10-30 wt .-%, preferably 14-25 wt .-%, most preferably 17-24 wt .-%, in each case based on the entire stick composition.

Preferred compositions according to the invention are characterized in that the wax component as constituent of the carrier of stick compositions according to the invention is selected from esters of a saturated, monohydric C ₁₆ -C ₆₀ -alkanol and a saturated C ₈ -C ₃₆ -monocarboxylic acid, in particular cetyl behenate, stearyl behenate and C ₂₀ C ₄₀ alkyl stearate, glycerol triesters of saturated linear C ₁₂ -C ₃₀ carboxylic acids which may be hydroxylated, candelilla wax, carnauba wax, beeswax, saturated linear C ₁₄ -C ₃₆ carboxylic acids and mixtures of the aforementioned substances. Particularly preferred wax component blends are selected from mixtures of cetyl behenate, stearyl behenate, hardened castor oil, palmitic acid and stearic acid. Further particularly preferred wax component mixtures are selected from mixtures of C ₂₀ -C ₄₀ -alkyl stearate, hardened castor oil, palmitic acid and stearic acid.

Particularly preferred compositions according to the invention are characterized in that the wax component is selected as constituent of the carrier according to the invention from mixtures of esters of a saturated, monohydric C ₁₆ -C ₆₀ alkanol and a saturated C ₈ -C ₃₆ monocarboxylic acid, in particular C ₂₀ -C ₄₀ alkyl stearate, glycerol triesters of saturated linear C ₁₂ -C ₃₀ carboxylic acids which may be hydroxylated, in particular hydrogenated castor oil, and saturated linear C ₁₄ -C ₃₆ carboxylic acids, in particular palmitic acid and stearic acid.

Further preferred compositions according to the invention are characterized in that the wax components as a constituent of the carrier according to the invention in a total amount of 1-10 wt .-%, preferably 1.5-8 wt .-%, particularly preferably 2-6 wt .-%, extraordinarily preferably 3-5 wt .-%, based on the total composition is included.

Further preferred compositions according to the invention are characterized in that at least one wax component having a melting point in the range of 25-50 ° C selected from Kokosfettsäureglycerinmono-, di- and triesters, Butyrospermum Parkii (shea butter) and esters of saturated, monohydric C ₈ -C ₁₈ alcohols with saturated C ₁₂ -C ₁₈ monocarboxylic acids and mixtures of these substances. These lower melting wax components allow for consistency optimization of the product and a minimization of the visible residue on the skin. Particularly preferred are commercial products with the INCI name Cocoglycerides, more preferably a mixture of C ₁₂ -C ₁₈ mono-, di- and triglycerides, which melts in the range of 30-32 ° C, as for example under the trade name Novata ^® AB from Cognis, as well as the products of the Softisan series (Sasol Germany GmbH) with the INCI name Hydrogenated Cocoglycerides, in particular Softisan 100, 133, 134, 138, 142. Further preferred esters of saturated, monohydric C ₁₂ -C ₁₈ - alcohols with saturated C ₁₂ -C ₁₈ monocarboxylic acids are stearyl laurate, cetearyl stearate (e.g., Crodamol ^® CSS.), stearyl stearate, cetyl palmitate (for example Cutina CP ^®, melting point (e.g. B Estol 3706th). 46-50 ° C .) and myristyl myristate (for example Cetiol ^® MM, melting point: 38-42 ° C).

Further preferred stick compositions according to the invention are characterized in that at least one wax component having a melting point in the range of 25-50 ° C, which is not fatty alcohol, in a total amount of 0.01 to 10 wt .-%, preferably 0.5-8 wt %, more preferably 1-5% by weight, and most preferably 1.1-4% by weight, based on the stick composition.

Further particularly preferred cosmetic or pharmaceutical compositions according to the invention which are suitable for body deodorization are characterized in that the at least one lipid or wax component having a melting point in the range from 25 to 50 ° C. is present in amounts of from 0.01 to 20% by weight 3-20 wt .-%, particularly preferably 5-18 wt .-% and most preferably 6-15 wt .-%, based on the total composition, is included.

Further preferred deodorant or antiperspirant sticks according to the invention are characterized in that the lipid or wax component (s) is generally added in amounts of 4-30% by weight, preferably 8-28% by weight, particularly preferably 15-25% by weight. %, exceptionally 20-23% by weight, based on the stick composition.

Anhydrous antiperspirant wax sticks contain about 40-60 wt .-% of at least one liquid under normal conditions cosmetic oil, about 15-28 wt .-% of a solid under normal fat component, of which usually about 80-85 wt .-% has a melting point of approx 50 ° C or usually from fatty alcohols, in particular stearyl alcohol, but also cetyl alcohol and optionally still arachidyl alcohol and / or behenyl alcohol, while a minor proportion - about 0.5-5 wt .-% - of at least one fatty component with a melting point of about 55-120 ° C consists. In addition, 0.5-5 wt .-% of at least one fat component having a melting point of about 25-35 ° C may be included. Furthermore, 0.5-10% by weight of at least one filler typically selected from talc, cellulose powders, starches and starch derivatives may be included. Furthermore, 0.1-10% by weight, preferably 1-5% by weight, more preferably 2-4% by weight, of at least one non-silicone-based oil-in-water emulsifier may be present.

In a particularly preferred embodiment of the invention, the anhydrous antiperspirant wax pen is present as a so-called multiphase pen, in particular as a two-phase pen. For the purposes of the present invention, pens are understood to include, for example, a first wax stick phase as the core and at least one second wax stick phase as a ring around the first phase. In addition to a concentric, annular arrangement of the individual phases, other arrangements are possible, in particular an arrangement in strip form. The individual phases can differ, for example, from different staining, but also from different constituents. Corresponding multiphase pins are disclosed, for example, in US Pat US 6936242 and WO 00/67712 A1 , Preferred manufacturing methods for such pins are in US 6838032 disclosed.

An embodiment as a multiphase pen, in particular as a two-phase pen, in which only one of the phases contains a specific active substance, is particularly preferred.

A preferred embodiment according to the invention as an anhydrous antiperspirant wax pencil is characterized in that it contains:
5-40%, preferably 10-35%, more preferably 11-28%, and most preferably 12-20% (USP) of at least one antiperspirant active,
30-70% by weight of at least one cosmetic 01 liquid under normal conditions,
15-32 wt .-% of a solid under normal conditions fat component, of which more than 65 wt .-%, preferably more than 70 wt .-%, particularly preferably more than 80 wt .-%, each based on the total content of solid under normal conditions Fat components, from C ₁₆ -C ₃₀ fatty alcohols, preferably selected from the group consisting of stearyl alcohol, cetyl alcohol and mixtures thereof, wherein more preferably in addition to stearyl alcohol and / or cetyl alcohol further 0.1-3 wt .-%, based is contained on the entire stick, arachidyl alcohol and / or behenyl alcohol and / or at least one C ₂₄ -C ₃₀ fatty alcohol,
further 0.5-5 wt .-%, based on the total stick, at least one fat component having a melting point of 75-120 ° C and 0.5-8 wt .-%, based on the total stick, at least one fat component with a melting point of 25-45 ° C,
furthermore 0.5-30% by weight, preferably 1-25% by weight, particularly preferably 5-20% by weight, extraordinarily
preferably 10-15% by weight, of at least one filler, which is particularly preferably selected from talc, cellulose powders, starches and starch derivatives.

Preferred compositions of the present invention, which are in the form of a spray or stick, preferably further contain at least one oil which is liquid at 20 ° C. and which does not constitute a perfume component and does not represent an essential oil.

The compositions of the invention contain at least one oil as a carrier fluid.

Antiperspirant compositions preferred according to the invention contain 30-95% by weight, preferably 40-93% by weight, more preferably 50-90% by weight, most preferably 55-85% by weight, based in each case on the total composition, on at least one liquid cosmetic liquid under normal conditions. A total amount of liquid under normal conditions cosmetic oils of 60, 63, 65, 68, 70, 73, 75, 78 or 80 wt .-%, each based on the total composition, according to the invention may be particularly preferred, with a total of 65 -73 wt .-% is particularly preferred.

In the case of cosmetic oils, a distinction is made between volatile and non-volatile oils. Non-volatile oils are understood as meaning oils having a vapor pressure of less than 2.66 Pa (0.02 mm Hg) at 20 ° C and an ambient pressure of 1013 hPa. Volatile oils are understood to mean those oils which, at 20 ° C. and an ambient pressure of 1013 hPa, have a vapor pressure of 2.66 Pa-40 000 Pa (0.02 mm-300 mm Hg), preferably 13-12000 Pa (0.1- 90 mm Hg), more preferably 15-8000 Pa, most preferably 300-3000 Pa.

Cosmetic oils preferred according to the invention are selected from silicone oils, to which z. As dialkyl and alkylaryl, such as cyclopentasiloxane, cyclohexasiloxane, dimethylpolysiloxane, low molecular weight phenyl trimethicone and methylphenylpolysiloxane, but also hexamethyldisiloxane, octamethyltrisiloxane and decamethyltetrasiloxane include. Particularly preferred are volatile silicone oils, which may be cyclic, such as. For example, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane and mixtures thereof, as described for. B. in the commercial products DC 244, 245, 344 and 345 of Dow Corning (vapor pressure at 20 ° C about 13-15 Pa) are included. Likewise particularly preferred are volatile linear silicone oils having 2-10 siloxane units, in particular hexamethyldisiloxane (L ₂ ), octamethyltrisiloxane (L ₃ ), decamethyltetrasiloxane (L ₄ ) and any mixtures of two and three of 12, 13 and / or 14, preferably such mixtures, as they are z. B. in the commercial products Dow Corning ^® 2-1184, Dow Corning ^® 200 (0.65 cSt), and Dow Corning ^® 200 (1.5 cSt) from Dow Corning are included. Another preferred volatile silicone oil is a low molecular weight phenyl trimethicone having a vapor pressure at 20 ° C of about 2000 Pa as available, for example, from GE Bayer Silicones / Momentive under the name Baysilone Fluid PD 5.

Volatile silicone oils are excellently suitable carrier oils for antiperspirant compositions which are preferred according to the invention, since they give them a pleasant feel on the skin and a low level of clothes soiling. According to the invention particularly preferred antiperspirant compositions are therefore by a content of at least one volatile silicone oil of 30-95 wt .-%, preferably 40-93 wt .-%, particularly preferably 50-90 wt .-%, most preferably 55-85 wt .-%, in each case based on the total composition characterized.

In addition to or instead of the at least one volatile silicone oil, at least one volatile non-silicone oil may also be present. Preferred volatile non-silicone oils are selected from C ₈ -C ₁₆ isoparaffins, especially isodecane, isoundecane, isododecane, isotridecane, isotetradecane, isopentadecane, and isohexadecane, and mixtures thereof. Preference is given to C ₁₀ -C ₁₃ isoparaffin mixtures, in particular those having a vapor pressure at 20 ° C. of about 300-400 Pa, preferably 360 Pa. Also this at least one volatile non-silicone oil is preferably in a total amount of 30-95 wt .-%, preferably 40-93 wt .-%, particularly preferably 50-90 wt .-%, most preferably 55-85 wt .-%, each based on the entire composition, included.

Because of the drier skin feel and the faster release of the active ingredient, volatile silicone oils, isoparaffins, in particular isodecane, isoundecane, isododecane, isotridecane, isotetradecane, isopentadecane, isohexadecane and isoeicosane, and mixtures of volatile silicone oils and isoparaffins, in particular isododecane, isohexadecane or isoeicosane, are particularly preferred ,

Preferred compositions according to the invention are characterized in that the at least one carrier oil which is liquid under normal conditions comprises at least one isoparaffin oil, in particular isodecane, isoundecane, isododecane, isotridecane, isotetradecane, isopentadecane, isohexadecane and isoeicosane. Further preferred compositions according to the invention are characterized in that the carrier oil which is liquid under normal conditions is a mixture of i) a volatile silicone oil selected from cyclomethicones and linear polydimethylsiloxanes with 2-10 siloxane units, and ii) at least one isoparaffin oil, isodecane, isoundecane, isododecane, Isotridecane, isotetradecane, isopentadecane, isohexadecane and isoeicosan.

In addition to the abovementioned substances, which are commonly referred to as "volatile" silicone oils, as well as the abovementioned volatile non-silicone oils, antiperspirant compositions which are particularly preferred according to the invention may further comprise at least one nonvolatile cosmetic oil selected from nonvolatile silicone oils and non-volatile non-silicone oils. The at least one non-volatile oil compensates for the negative effect of the volatile oil on the residue behavior according to the invention preferred antiperspirant compositions. Due to the relatively rapid evaporation of the volatile oils, solid, insoluble constituents, in particular the antiperspirant active ingredients, can be seen on the skin as an unpleasant residue. These residues can be successfully masked with a nonvolatile oil. In addition, parameters such as skin feel, residue visibility and suspension stability can be fine-regulated with a mixture of non-volatile and volatile oils and better adapted to consumer needs.

Of course, it is also possible to formulate anhydrous antiperspirant compositions with a low level of volatile oils or even without volatile oils.

Preferred nonvolatile silicone oils are selected from higher molecular weight linear dimethylpolysiloxanes, commercially available e.g. Example under the name Dow Corning ^® 190, Dow Corning ^® 200 fluid having kinematic viscosities (25 ° C) in the range of 5-100 cSt, preferably 6-50 cSt, or even 5-10 cSt, and Baysilon ^® 350 M (with a kinematic viscosity (25 ° C) of about 350 cSt.

Silicone oils which are likewise preferred according to the invention are selected from silicones of the formula (Sil-1), where x is selected from integers of 1-20.

A preferred silicone oil of formula (Sil-1) is available under the INCI name Phenyl Trimethicone in various grades, viscosities and volatilities. A non-volatile phenyl trimethicone is available, for example, from Dow Corning under the name Dow Corning 556.

Natural and synthetic hydrocarbons such as liquid paraffins, C ₁₈ -C ₃₀ isoparaffins, in particular isoeicosane, polyisobutenes or polydecenes, the ^®, for example, under the designation Emery ^® 3004, 3006, 3010 or under the name Ethylflo ^® from Albemarle or Nexbase 2004G from Nestle are available, as well as 1,3-di- (2-ethylhexyl) -cyclohexane (obtainable, for. example, under the trade name Cetiol ^® S from Cognis) also belong to the present invention the preferred non-volatile non-silicone oils.

Further non-volatile non-silicone oils which are preferred according to the invention are selected from the benzoic acid esters of linear or branched C _8-22 -alkanols. Particularly preferred are benzoic C12-C15 alkyl esters, z. B. available as a commercial product Finsolv ^® TN, benzoic acid isostearyl, z. B. available as a commercial product Finsolv ^® SB, ethylhexyl benzoate, z. B. available as a commercial product Finsolv ^® EB, and Benzoesäureoctyldocecylester, z. B. available as a commercial product Finsolv ^® BOD. Benzoic acid ester oils of this type are particularly suitable for masking antiperspirant active substance residues, since their refractive index comes very close to the particularly effective aluminum-zirconium mixed salts.

Further non-volatile non-silicone oils which are preferred according to the invention are selected from branched saturated or unsaturated fatty alcohols having 6-30 carbon atoms. These alcohols are also often referred to as Guerbet alcohols, as they are obtainable by the Guerbet reaction. Preferred alcohol oils are Hexyldecanol (Eutanol ^® G 16, Guerbitol ^® T 16) Octyldodecanol (Eutanol ^® G, Guerbitol ^® 20), 2-ethyl hexyl alcohol, and the products sold Guerbitol ^® 18, Isofol ^® 12, Isofol ^® 16, Isofol ^® 24, Isofol ^® 36, Isocarb 12 ^{®, ®} Isocarb 16 or Isocarb ^® 24th

Other preferred non-volatile non-silicone oils are selected from mixtures of Guerbet alcohols and Guerbet alcohol esters, e.g. As the commercial product Cetiol ^® PGL (hexyldecanol and hexyldecyl laurate).

Further non-volatile non-silicone oils which are preferred according to the invention are selected from the triglycerides of linear or branched, saturated or unsaturated, optionally hydroxylated C ₃ -fatty acids. Particularly suitable, the use of natural oils, eg. Example, soybean oil, cottonseed oil, sunflower oil, palm oil, palm kernel oil, linseed oil, almond oil, castor oil, corn oil, rapeseed oil, olive oil, sesame oil, thistle oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil and the like. But are also synthetic triglyceride oils, in particular Capric / Caprylic triglycerides, z. As the commercial products Myritol ^® 318, Myritol ^® 331 (Cognis) or Miglyol ^® 812 (Hüls) with unbranched fatty acid residues and glyceryl triisostearin and the commercial products Estol ^® GTEH 3609 (Unigema) or Myritol ^® GTEH (Cognis) with branched fatty acid residues.

Further non-volatile non-silicone oils which are particularly preferred according to the invention are selected from the dicarboxylic acid esters of linear or branched C ₂ -C ₁₀ -alkanols, in particular diisopropyl adipate, di-n-butyl adipate, di- (2-ethylhexyl) adipate, dioctyl adipate, diethyl / di-n- butyl / dioctyl sebacate, diisopropyl sebacate, dioctyl malate, dioctyl maleate, dicaprylyl maleate, diisooctyl succinate, di-2-ethylhexyl succinate and di- (2-hexyldecyl) succinate.

Further non-volatile non-silicone oils particularly preferred according to the invention are selected from the esters of linear or branched saturated or non-volatile non-silicone oils unsaturated fatty alcohols having 2-30 carbon atoms with linear or branched saturated or unsaturated fatty acids having 2-30 carbon atoms, which may be hydroxylated. These include isopropyl myristate, isopropyl palmitate, isopropyl stearate, hexyldecyl stearate (Eutanol ^® G 16 S), hexyldecyl laurate, isononyl isononanoate, 2-ethylhexyl palmitate (Cegesoft ^® C 24) and 2-ethylhexyl stearate (Cetiol ^® 868). Also preferred are isooctyl stearate, isononyl stearate, isocetyl stearate, isononyl isononanoate, isotridecyl isononanoate, cetearyl isononanoate, 2-ethylhexyl laurate, 2-ethylhexyl isostearate, 2-ethylhexyl cocoate, 2-octyl dodecyl palmitate, butyloctanoic acid 2-butyl octanoate, diisotridecyl acetate, n-hexyl laurate, n-decyl oleate, oleyl oleate, oleyl erucate , Erucyl oleate and erucyl erucate.

Further inventively particularly preferred non-volatile non-silicone oils are selected from the addition products of 1 to 5 propylene oxide units of mono- or polyhydric C _8-22 alkanols such as octanol, decanol, decanediol, lauryl alcohol, myristyl alcohol and stearyl alcohol, eg. B. PPG-2 myristyl ether and PPG-3 myristyl ether (Witconol APM ^®).

Further non-volatile non-silicone oils which are particularly preferred according to the invention are selected from the adducts of at least 6 ethylene oxide and / or propylene oxide units with _monohydric or polyhydric C _8-22 alkanols such as glycerol, butanol, butanediol, myristyl alcohol and stearyl alcohol, which may be esterified if desired, z. As PPG-14 butyl ether (Ucon Fluid ^® AP), PPG-9-butyl ether (Breox ^® 625), PPG-10 butanediol (Macol ^® 57), PPG-15 stearyl ether (Arlamol ^® E), and Glycereth-7 -diisononanoat.

Cosmetic or pharmaceutical compositions suitable for body deodorization according to the invention are collectively characterized in that they contain 1-30% by weight, preferably 2.5-27.5% by weight, more preferably 5%, based on the weight of the ready-to-use composition -25 wt .-% and most preferably 5-20 wt .-% fatty alcohol (s) and / or PEG ethers of fatty alcohols and / or PPG ethers of fatty alcohols.

Further inventively particularly preferred non-volatile non-silicone oils are selected from the symmetrical, asymmetrical or cyclic esters of carbonic acid with fatty alcohols, eg. As glycerol carbonate, dicaprylyl carbonate (Cetiol ^® CC) or the esters according to the teaching of DE 19756454 A1 , Further oils which may be preferred according to the invention are selected from the esters of dimers of unsaturated C ₁₂ -C ₂₂ -fatty acids (dimer fatty acids) with monovalent linear, branched or cyclic C ₂ -C ₁₈ -alkanols or with polyvalent linear or branched C ₂ - C ₆ alkanols.

It may be preferred according to the invention to use mixtures of the aforementioned oils.

Preferred compositions according to the invention are characterized in that the carrier oil which is liquid under normal conditions is selected from volatile silicone oils, nonvolatile silicone oils, volatile hydrocarbon oils, branched saturated or unsaturated fatty alcohols having 6-30 carbon atoms, triglycerides of linear or branched, saturated or unsaturated, optionally hydroxylated C _8-30 fatty acids, dicarboxylic acid esters of linear or branched C ₂ -C ₁₀ -alkanols, esters of branched saturated or unsaturated fatty alcohols having 2-30 carbon atoms with linear or branched saturated or unsaturated fatty acids having 2-30 carbon atoms which may be hydroxylated, addition products of 1 to 5 propylene oxide units of mono- or polyhydric C _8-22 alkanols, addition products of at least 6 ethylene oxide and / or propylene oxide units to mono- or polyvalent C _{3 22} -alkanols, C ₈ -C ₂₂ -fatty alcohol esters of monohydric or polyhydric C ₂ -C ₇ -hydroxycarboxylic acids, symmetrical, unsymmetrical or cyclic esters of carbonic acid with fatty alcohols, the esters of dimers of unsaturated C ₁₂ -C ₂₂ -fatty acids (dimer fatty acids) with monohydric linear, branched or cyclic C ₂ -C ₁₈ -alkanols or with polyvalent ones en linear or branched C ₂ -C ₆ -alkanols, and mixtures of the aforementioned substances.

It may be extraordinarily preferred according to the invention to use mixtures of the abovementioned oils in order to achieve optimum fine-tuning of the product properties, in particular the residue behavior, the feel of the skin or the release of the active ingredient.

Particularly preferred compositions according to the invention are characterized in that the carrier oil which is liquid under normal conditions is a mixture of at least one volatile silicone oil and at least one oil of another type. These are preferably mixtures of at least one volatile silicone oil and at least one non-silicone oil selected from volatile hydrocarbon oils, branched saturated or unsaturated fatty alcohols having 6-30 carbon atoms, triglycerides of linear or branched, saturated or unsaturated, optionally hydroxylated C _8-30 fatty acids , Dicarboxylic acid esters of linear or branched C ₂ -C ₁₀ -alkanols, esters of branched saturated or unsaturated fatty alcohols having 2-30 carbon atoms with linear or branched saturated or unsaturated fatty acids having 2-30 carbon atoms which may be hydroxylated, addition products of 1 to 5 Propylene oxide units of mono- or polyhydric C _8-22 alkanols, addition products of at least 6 ethylene oxide and / or propylene oxide units of mono- or polyhydric C _3-22 alkanols, C ₈ -C ₂₂ fatty alcohol esters of monovalent or polyvalent C ₂ -C ₇ hydroxycarbons acids, symmetrical, unsymmetrical or cyclic esters of carbonic acid with fatty alcohols, the esters of dimers of unsaturated C ₁₂ -C ₂₂ fatty acids (dimer fatty acids) with monovalent linear, branched or cyclic C ₂ -C ₁₈ alkanols or with polyvalent linear or branched C ₂ -C ₆ -alkanols, and mixtures of the aforementioned substances.

Further oil component types which are particularly preferred according to the invention are isoparaffin oils, in particular isododecane, isohexadecane and isoeicosane. Isododecane, isohexadecane and isoeicosane are among the volatile oil components. Since they evaporate relatively quickly after application to the skin, the hydrophobic loading of the antiperspirant active ingredient particles is reduced. Such volatile oil components thus assist the release of the antiperspirant active.

According to a further, likewise preferred embodiment, the anhydrous antiperspirant compositions according to the invention contain a small proportion of at most 2% by weight, preferably not more than 1% by weight, of cyclomethicones or are even free of cyclomethicones. Particularly suitable substitutes for cyclomethicones are the C ₈ -C ₁₆ isoparaffins, in particular those selected from isononane, isodecane, isoundecane, isododecane, isotridecane, isotetradecane, isopentadecane, and isohexadecane, and also mixtures thereof. Preference is given to C ₁₀ -C ₁₃ isoparaffin mixtures, in particular those having a vapor pressure at 20 ° C. of about 300-400 Pa, preferably 360 Pa.

In addition to the at least one aforementioned C ₈ -C ₁₆ isoparaffin further preferred antiperspirant compositions according to the invention contain from 0 to at most 2 wt .-%, preferably at most 1 wt .-% of cyclomethicones at least one non-volatile cosmetic oil selected from non-volatile silicone oils and non-volatile non-silicone oils. The at least one non-volatile oil compensates for the negative effect of the volatile isoparaffin on the residue behavior of preferred antiperspirant compositions according to the invention. Due to the relatively rapid evaporation of the volatile oils, solid, insoluble constituents, in particular the antiperspirant active ingredients, can be seen on the skin as an unpleasant residue. These residues can be successfully masked with a nonvolatile oil. In addition, with a mixture of non-volatile and volatile oils, parameters such as skin feel, residue visibility and suspension stability can be fine-tuned and better adapted to consumer needs. To this end particularly preferred non-volatile oils are especially the Esteröle 2-ethylhexyl palmitate (z. B. Cegesoft ^® C 24), hexyldecyl laurate, 2-ethylhexyl stearate, isopropyl myristate, isopropyl palmitate and 2-ethylhexyl laurate, the benzoic acid esters of linear or branched C _8-22 alkanols, in particular the commercially available product ^® Finsolv TN (C ₁₂ -C ₁₅ -alkyl), C ₁₂ -C ₁₅ alkyl lactate and di-C ₁₂ -C ₁₃ -Alkylmalat suitable. Furthermore, it may be particularly preferred according to the invention formulate anhydrous antiperspirant compositions without cyclomethicones and without volatile linear silicone oils. Here, too, are particularly preferred the Esteröle 2-ethylhexyl palmitate (z. B. Cegesoft ^® C 24), hexyldecyl laurate, 2-ethylhexyl stearate, isopropyl myristate, isopropyl palmitate and 2-ethylhexyl laurate, the benzoic acid esters of linear or branched C _8-22 -alkanols, in particular the commercial product Finsolv ^® TN (C ₁₂ -C ₁₅ -alkyl), C ₁₂ -C ₁₅ alkyl lactate and di-C ₁₂ -C ₁₃ -Alkylmalat suitable.

According to the invention particularly preferred oil mixtures having 0 to a maximum of 2 wt .-%, preferably 0 to a maximum of 1 wt .-%, of cyclomethicones are 2-ethylhexyl palmitate / isodecane / isoundecane / isododecane / isotridecane, hexyldecyl laurate / isodecane / isoundecane / isododecane / isotridecane, 2nd Ethylhexyl stearate / isodecane / isoundecane / isododecane / isotridecane, isopropyl myristate / isodecane / isoundecane / isododecane / isotridecane, isopropyl palmitate / isononane / isodecane / isoundecane / isododecane / isotridecane, 2-ethylhexyl laurate / isodecane / isoundecane / isododecane / isotridecane, C ₁₂ -C ₁₅ Alkyl lactate / isodecane / isoundecane / isododecane / isotridecane, C ₁₂ -C ₁₅ alkyl benzoate / isodecane / isoundecane / isododecane / isotridecane and di-C ₁₂ -C ₁₃ alkyl malate / isodecane / isoundecane / isododecane / isotridecane.

In preferred oil mixtures with 0 to a maximum of 2 wt .-%, preferably 0 to a maximum of 1 wt .-%, of cyclomethicones, the two types of oil (ester / C ₈ -C ₁₆ isoparaffin) in equal proportions by weight. Further preferred weight ratios of ester / C _8-16 isoparaffin are (0.6-1) :( 1-3). Further preferred weight ratios ester / C ₈ -C ₁₆ isoparaffin are 1: (1-1.5). Further preferred weight ratios ester / C ₈ -C ₁₆ isoparaffin are (0.6-0.9) :( 2.5-3), in particular 0.8: 3.

In further preferred oil mixtures with 0 to a maximum of 2 wt .-%, preferably 0 to a maximum of 1 wt .-%, of cyclomethicones, the two types of oil isopropyl myristate / C ₈ -C ₁₆ isoparaffin in equal proportions by weight. Further preferred weight ratios of isopropyl myristate / C _8-16 isoparaffin are (0.6-1) :( 1-3). Further preferred weight ratios of isopropyl myristate / C ₈ -C ₁₆ isoparaffin are 1: (1-1.5). Further preferred weight ratios of isopropyl myristate / C ₈ -C ₁₆ isoparaffin are (0.6-0.9) :( 2.5-3), in particular 0.8: 3.

In further preferred oil mixtures with 0 to a maximum of 2 wt .-%, preferably 0 to a maximum of 1 wt .-%, of cyclomethicones, the two types of oil isopropyl palmitate / C ₈ -C ₁₆ isoparaffin in equal proportions by weight. Further preferred weight ratios of isopropyl palmitate / C _8-16 isoparaffin are (0.6-1) :( 1-3). Further preferred weight ratios of isopropyl palmitate / C ₈ -C ₁₆ isoparaffin are 1: (1-1.5). Further preferred weight ratios of isopropyl palmitate / C ₈ -C ₁₆ isoparaffin are (0.6-0.9) :( 2.5-3), in particular 0.8: 3.

In further preferred oil mixtures with 0 to a maximum of 2 wt .-%, preferably 0 to a maximum of 1 wt .-%, of cyclomethicones, the two types of oil 2-ethylhexyl palmitate / C ₈ -C ₁₆ isoparaffin in equal proportions by weight. Further preferred weight ratios of 2-ethylhexyl palmitate / C _8-16 isoparaffin are (0.6-1) :( 1-3). Further preferred weight ratios of 2-ethylhexyl palmitate / C ₈ -C ₁₆ isoparaffin are 1: (1-1.5). Further preferred weight ratios of 2-ethylhexyl palmitate / C ₈ -C ₁₆ isoparaffin are (0.6-0.9) :( 2.5-3), in particular 0.8: 3.

In further preferred oil mixtures with 0 to a maximum of 2% by weight, preferably 0 to a maximum of 1% by weight, of cyclomethicones, the two oil types C ₁₂ -C ₁₅ -alkyl benzoate / C ₈ -C ₁₆ -isoparaffin are present in equal parts by weight. Further preferred weight ratios C ₁₂ -C ₁₅ alkyl benzoate / C _8-16 isoparaffin are (0.6-1) :( 1-3). Further preferred weight ratios C ₁₂ -C ₁₅ alkyl benzoate / C ₈ -C ₁₆ isoparaffin are 1: (1-1.5). Further preferred weight ratios C ₁₂ -C ₁₅ -alkyl benzoate / C ₈ -C ₁₆ isoparaffin are (0.6-0.9): (2.5-3), in particular 0.8: 3.

In further preferred oil mixtures with 0 to at most 2 wt .-%, preferably 0 to a maximum of 1 wt .-%, of cyclomethicones, the two types of oil ester / C ₁₀ -C ₁₃ isoparaffin in equal proportions by weight. Further preferred weight ratios of ester / C _10-13 isoparaffin are (0.6-1) :( 1-3). Further preferred weight ratios ester / C ₁₀ -C ₁₃ isoparaffin are 1: (1-1.5). Further preferred weight ratios ester / C ₁₀ -C ₁₃ isoparaffin are (0.6-0.9) :( 2.5-3), in particular 0.8: 3.

In further preferred oil mixtures with 0 to a maximum of 2 wt .-%, preferably 0 to a maximum of 1 wt .-%, of cyclomethicones, the two types of oil isopropyl myristate / C ₁₀ -C ₁₃ isoparaffin in equal proportions by weight. Further preferred weight ratios of isopropyl myristate / C _10-13 isoparaffin are (0.6-1) :( 1-3). Further preferred weight ratios isopropyl myristate / C ₁₀ -C ₁₃ - Isoparaffin is 1: (1-1.5). Further preferred weight ratios of isopropyl myristate / C ₁₀ -C ₁₃ isoparaffin are (0.6-0.9) :( 2.5-3), in particular 0.8: 3.

In further preferred oil mixtures with 0 to a maximum of 2 wt .-%, preferably 0 to a maximum of 1 wt .-%, of cyclomethicones, the two types of oil isopropyl palmitate / C ₁₀ -C ₁₃ isoparaffin in equal proportions by weight. Further preferred weight ratios of isopropyl palmitate / C _10-13 isoparaffin are (0.6-1) :( 1-3). Further preferred weight ratios of isopropyl palmitate / C ₁₀ -C ₁₃ isoparaffin are 1: (1-1.5). Further preferred weight ratios of isopropyl palmitate / C ₁₀ -C ₁₃ isoparaffin are (0.6-0.9) :( 2.5-3), in particular 0.8: 3.

In further preferred oil mixtures with 0 to a maximum of 2 wt .-%, preferably 0 to a maximum of 1 wt .-%, of cyclomethicones, the two types of oil 2-ethylhexyl palmitate / C ₁₀ -C ₁₃ isoparaffin in equal proportions by weight. Further preferred weight ratios of 2-ethylhexyl palmitate / C _10-13 isoparaffin are (0.6-1) :( 1-3). Further preferred weight ratios of 2-ethylhexyl palmitate / C ₁₀ -C ₁₃ isoparaffin are 1: (1-1.5). Further preferred weight ratios of 2-ethylhexyl palmitate / C ₁₀ -C ₁₃ isoparaffin are (0.6-0.9) :( 2.5-3), in particular 0.8: 3.

In further preferred oil mixtures with 0 to a maximum of 2% by weight, preferably 0 to a maximum of 1% by weight, of cyclomethicones, the two oil types C ₁₂ -C ₁₅ -alkyl benzoate / C ₁₀ -C ₁₃ -isoparaffin are contained in equal proportions by weight. Further preferred weight ratios C ₁₂ -C ₁₅ alkyl benzoate / C _10-13 isoparaffin are (0.6-1) :( 1-3). Further preferred weight ratios C ₁₂ -C ₁₅ alkyl benzoate / C ₁₀ -C ₁₃ isoparaffin are 1: (1-1.5). More preferred weight ratios of C ₁₂ -C _{1 5} alkyl benzoate / C ₁₀ -C ₁₃ isoparaffin is (0.6-0.9): (2.5-3), particularly 0.8: 3rd

The compositions according to the invention are preferably in the form of a suspension, that is to say the antiperspirant active ingredient and optionally further insoluble constituents are suspended in a liquid carrier which is optionally thickened or solidified into a stick.

Further particularly preferred compositions according to the invention which are suitable for body deodorization according to the invention are characterized in that the oil (s) which are liquid at 20 ° C. are present in a total amount of 0.1-80% by weight, preferably 2-20% by weight. -%, more preferably 3-15 wt .-%, each based on the total weight of the composition, is / are included.

Compositions which are particularly preferred according to the invention furthermore preferably contain at least one skin-cooling active substance. Skin-cooling active ingredients suitable according to the invention are, for example, menthol, isopulegol and menthol derivatives, eg. Menthyl lactate, menthyl glycolate, menthyl pyrrolidone carboxylic acid, menthyl methyl ether, menthoxypropanediol, menthone glycerol acetal (9-methyl-6- (1-methylethyl) -1,4-dioxaspiro (4.5) decane-2-methanol), monomethyl succinate and 2-hydroxymethyl-3,5 , 5-trimethylcyclohexanol. Preferred skin-cooling active ingredients are menthol, isopulegol, menthyl lactate, menthoxypropanediol and menthylpyrrolidonecarboxylic acid, and mixtures of these substances, in particular mixtures of menthol and menthyl lactate, menthol, menthol glycolate and menthyl lactate, menthol and menthoxypropanediol or menthol and isopulegol.

It is particularly preferred according to the invention for at least one skin-cooling active substance to be present in a total amount of 0.01-1% by weight, more preferably 0.02-0.5% by weight and most preferably 0.05-0.2% by weight. %, in each case based on the total weight of the composition. Particularly preferred compositions according to the invention, which are formulated as a propellant-driven aerosol, contain at least one propellant. Preferred propellants (propellants) are propane, propene, n-butane, isobutane, isobutene, n-pentane, pentene, isopentane, isopentene, methane, ethane, dimethyl ether, nitrogen, air, oxygen, nitrous oxide, 1,1,1,3-tetrafluoroethane, heptafluoro-n-propane, perfluoroethane, monochlorodifluoromethane, 1,1-difluoroethane, both individually and in combination. Also hydrophilic propellants, such. As carbon dioxide, can be used advantageously in the context of the present invention, when the proportion of hydrophilic gases is selected low and lipophilic propellant gas (eg., Propane / butane) is present in excess. Particularly preferred are propane, n-butane, isobutane and mixtures of these propellants. It has been found that the use of n-butane as the only propellant gas according to the invention can be particularly preferred.

The amount of blowing agent is preferably 20-80 wt .-%, more preferably 30-70 wt .-% and most preferably 40-50 wt .-%, each based on the total weight of the preparation consisting of the composition of the invention and the blowing agent ,

As pressure gas container come vessels made of metal (aluminum, tinplate, tin), protected or non-splitterndem plastic or glass, which is coated with plastic outside, in question, in their selection pressure and fracture resistance, corrosion resistance, easy fillability as well as aesthetic Aspects, handiness, printability etc. play a role. Special internal protective lacquers ensure corrosion resistance to the composition according to the invention. polyols

Preferred compositions according to the invention also contain at least one water-soluble polyhydric C ₂ -C ₉ -alkanol having 2-6 hydroxyl groups and / or at least one water-soluble polyethylene glycol having 3-20 ethylene oxide units and mixtures thereof. These components are preferably selected from 1,2-propylene glycol, 2-methyl-1,3-propanediol, glycerol, Butylene glycols such as 1,2-butylene glycol, 1,3-butylene glycol and 1,4-butylene glycol, pentylene glycols such as 1,2-pentanediol and 1,5-pentanediol, hexanediols such as 1,6-hexanediol, hexanetriols such as 1,2,6- Hexanetriol, 1,2-octanediol, 1,8-octanediol, dipropylene glycol, tripropylene glycol, diglycerol, triglycerol, erythritol, sorbitol and mixtures of the aforementioned substances. Suitable water-soluble polyethylene glycols are selected from PEG-3, PEG-4, PEG-6, PEG-7, PEG-8, PEG-9, PEG-10, PEG-12, PEG-14, PEG-16, PEG-18 and PEG-20 and mixtures thereof, with PEG-3 to PEG-8 being preferred.

Preferred cosmetic of the present invention or pharmaceutical composition suitable for Körperdeodorierung compositions are characterized in that the at least one water-soluble polyhydric C ₂ -C ₉ alkanol with 2-6 hydroxyl groups and / or at least one water-soluble polyethylene glycol is selected with 3-20 ethylene oxide units from 1 , 2-propylene glycol, 2-methyl-1,3-propanediol, glycerol, butylene glycols such as 1,2-butylene glycol, 1,3-butylene glycol and 1,4-butylene glycol, pentylene glycols such as 1,2-pentanediol and 1,5-pentanediol , Hexanediols such as 1,6-hexanediol, hexanetriols such as 1,2,6-hexanetriol, 1,2-octanediol, 1,8-octanediol, dipropylene glycol, tripropylene glycol, diglycerol, triglycerol, erythritol, sorbitol and mixtures of the aforementioned substances.

Particularly preferred cosmetic or pharmaceutical compositions of the invention suitable for body deodorization are characterized in that the at least one water-soluble polyhydric C ₂ -C ₉ -alkanol with 2-6 hydroxyl groups and / or at least one water-soluble polyethylene glycol with 3-20 ethylene oxide units in total in quantities from 3-30 wt .-%, preferably 8-25 wt .-%, particularly preferably 10-18 wt .-%, each based on the total composition is included. fillers

Particularly preferred cosmetic or pharmaceutical compositions suitable for body deodorization according to the invention are characterized in that they further contain at least one solid, water-insoluble particulate filler for improving the stick consistency and the sensory properties. In a highly preferred embodiment of this filler is selected from optionally modified starches (for. Example, of corn, rice, potatoes) and starch derivatives, which are, if desired, pregelatinized, in particular starch derivatives of type DRY FLO ^®, cellulose and cellulose derivatives, silica, silicic acids, e.g. , As Aerosil ^® types, spherical Polyalkylsesquisiloxan particles (especially Aerosil ^® R972 and Aerosil ^® 200 V from Degussa), silica gels, boron nitride, lactoglobulin derivatives, eg. As sodium C _8-16 -Isoalkylsuccinyllactoglobulinsulfonat from Brooks Industries available as a commercial product Biopol ^® OE, glass powders, polymer powders, in particular of polyolefins, polycarbonates, polyurethanes, polyamides, z. As nylon, polyesters, polystyrenes, polyacrylates, (meth) acrylate or (meth) acrylate-vinylidene copolymers, which may be crosslinked, or silicones, and mixtures of these substances.

Polymer powder based on a polymethacrylate copolymer are z. B. as a commercial product Polytrap ^® 6603 (Dow Corning) available. Other polymer powders, e.g. Example based on polyamides, obtainable under the name Orgasol ^® 1002 (polyamide-6) and Orgasol ^® 2002 (polyamide-12) from Elf Atochem. Other polymer powders which are suitable for the purpose according to the invention are, for. B. polymethacrylates (Micro Pearl ^® M from SEPPIC or Plastic Powder A of NIKKOL), styrene-divinylbenzene copolymers (Plastic Powder FP of NIKKOL), polyethylene and polypropylene powder (ACCUREL ^® EP 400 from AKZO), or silicone polymers (Silicone Powder X2-1605 from Dow Corning).

Particularly preferred cosmetic or pharmaceutical compositions according to the invention which are suitable for body deodorization are characterized in that they contain at least one solid, water-insoluble particulate filler in a total amount of from 0.01 to 30% by weight, preferably 5 to 20% by weight, more preferably 8 -15 wt .-%, each based on the total composition.

fragrances

Particularly preferred cosmetic or pharmaceutical compositions according to the invention which are suitable for body deodorization are characterized in that at least one perfume component is furthermore present.

As perfume component perfumes, perfume oils or perfume oil ingredients can be used. Perfume oils or fragrances can according to the invention individual fragrance compounds, eg. As the synthetic products of the ester type, ethers, aldehydes, ketones, alcohols and hydrocarbons. Fragrance compounds of the ester type are e.g. Benzyl acetate, phenoxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethylbenzylcarbinylacetate (DMBCA), phenylethylacetate, benzylacetate, ethylmethylphenylglycinate, allylcyclohexylpropionate, styrallylpropionate, benzylsalicylate, cyclohexylsalicylate, floramate, melusate and jasmecyclate. The ethers include, for example, benzyl ethyl ether and ambroxane, to the aldehydes z. B. the linear alkanals with 8-18 C-atoms, citral, citronellal, citronellyloxy-acetaldehyde, cyclamen aldehyde, Lilial and Bourgeonal, to the ketones z. B. the Jonone, alpha- Isomethylionone and Methylcedrylketon, to the alcohols anethole, citronellol, eugenol, geraniol, linalool, phenylethyl alcohol and terpineol, the hydrocarbons include mainly the terpenes such as limonene and pinene. Preferably, however, mixtures of different fragrances are used, which together produce an attractive fragrance.

Such perfume oils may also contain natural fragrance mixtures as are available from vegetable sources, e.g. Pine, citrus, jasmine, patchouly, rose or ylang-ylang oil. Also suitable are Muskateller sage oil, chamomile oil, clove oil, lemon balm oil, mint oil, cinnamon leaf oil, lime blossom oil, juniper berry oil, vetiver oil, olibanum oil, galbanum oil and labdanum oil and orange blossom oil, neroli oil, orange peel oil and sandalwood oil.

In order to be perceptible, a fragrance must be volatile, whereby besides the nature of the functional groups and the structure of the chemical compound, the molecular weight also plays an important role. For example, most odorants have molecular weights up to about 200 daltons, while molecular weights of 300 daltons and above are more of an exception. Due to the different volatility of fragrances, the smell of a perfume or fragrance composed of several fragrances changes during evaporation, whereby the odor impressions in "top note", "middle note or body" and "base note" (end note or dry out). Since odor perception is also largely based on the odor intensity, the top note of a perfume or fragrance does not consist solely of volatile compounds, while the base note consists largely of less volatile, d. H. adherent fragrances. For example, in the composition of perfumes, more volatile fragrances can be bound to certain fixatives, preventing them from evaporating too quickly. In the subsequent classification of the fragrances in "more volatile" or "adherent" fragrances so nothing about the olfactory impression and whether the corresponding fragrance is perceived as a head or middle note, nothing said.

Adhesion-resistant fragrances which can be used in the context of the present invention are, for example, the essential oils such as angelica root oil, aniseed oil, arnica blossom oil, basil oil, bay oil, bergamot oil, Champacablütenöl, Edel fir oil, Edeltannenzapfen oil, Elemiöl, eucalyptus oil, fennel oil, spruce needle oil, galbanum oil, geranium oil, ginger grass oil, Guaiac wood oil, gurdy balm oil, helichrysum oil, ho oil, ginger oil, iris oil, cajeput oil, calamus oil, camomile oil, camphor oil, kanga oil, cardamom oil, cassia oil, pine oil, copaiba balsam, coriander oil, spearmint oil, caraway oil, cumin oil, lavender oil, lemongrass oil, lime oil, tangerine oil, lemon balm oil, Musk Grain Oil, Myrrh Oil, Clove Oil, Neroli Oil, Niaouli Oil, Olibanum Oil, Orange Oil, Origanum Oil, Palmarosa Oil, Patchouli Oil, Peru Balsam Oil, Petitgrain Oil, Pepper Oil, Peppermint Oil, Pimento Oil, Pine Oil, Rose Oil, Rosemary Oil, Sandalwood Oil, Celery Oil, Spik Oil, Star Aniseed Oil, Turpentine Oil, Thuja Oil, Thyme oil, Verbe oil, vetiver oil, juniper berry oil, wormwood oil, wintergreen oil, ylang-ylang oil, hyssop oil, cinnamon oil, cinnamon oil, citronella oil, lemon oil and cypress oil. But also the higher-boiling or solid fragrances of natural or synthetic origin can be used in the context of the present invention as adherent fragrances or fragrance mixtures, ie fragrances. These compounds include the following compounds and mixtures thereof: ambrettolide, α-amylcinnamaldehyde, anethole, anisaldehyde, anisalcohol, anisole, methyl anthranilate, acetophenone, benzylacetone, benzaldehyde, ethyl benzoate, benzophenone, benzyl alcohol, benzyl acetate, benzyl benzoate, benzyl formate, benzyl valerate, borneol , Bornyl acetate, α-bromostyrene, n-decyl aldehyde, n-dodecyl aldehyde, eugenol, eugenol methyl ether, eucalyptol, farnesol, fenchone, fenchyl acetate, geranyl acetate, geranyl formate, heliotropin, heptincarboxylic acid methyl ester, heptaldehyde, hydroquinone dimethyl ether, hydroxycinnamaldehyde, hydroxycinnamyl alcohol, indole, iron, isoeugenol , Isoeugenol methyl ether, isosafrole, jasmon, camphor, karvakrol, karvon, p-cresol methyl ether, coumarin, p-methoxyacetophenone, methyl n-amyl ketone, methyl anthranilate, p-methylacetophenone, methylchavikole, p-methylquinoline, methyl-β-naphthyl ketone, methyl-n nonylacetaldehyde, methyl n-nonyl ketone, Muskon, β-Na phthol ethyl ether, β-naphthol methyl ether, nerol, nitrobenzene, n-nonylaldehyde, nonyl alcohol, n-octylaldehyde, p-oxy-acetophenone, pentadecanolide, β-phenylethyl alcohol, phenylacetaldehyde dimethyacetal, phenylacetic acid, pulegone, safrole, isoamyl salicylate, methyl salicylate, hexyl salicylate, cyclohexyl salicylate, Santalol, skatole, terpineol, thymen, thymol, γ-undelactone, vaniline, veratrum aldehyde, cinnamaldehyde, cimat alcohol, cinnamic acid, cinnamic acid ethyl ester, cinnamic acid benzyl ester.

The more volatile fragrances include in particular the lower-boiling fragrances of natural or synthetic origin, which can be used alone or in mixtures. Examples of more volatile fragrances are alkyl isothiocyanates (alkylmustard oils), butanedione, limonene, linalool, linayl acetate and propionate, menthol, menthone, methyl-n-heptenone, phellandrene, phenylacetaldehyde, terpinyl acetate, citral, citronellal.

A preferred embodiment of the present invention are cosmetic or pharmaceutical compositions suitable for body deodorization, which by weight the ready-to-use composition - 0.05 to 5 wt .-%, preferably 0.1 to 3 wt .-% and in particular 0.25 to 2 wt .-% perfume oils.

Another preferred embodiment of the present invention are cosmetic or pharmaceutical compositions suitable for body deodorization which, based on the weight of the ready-to-use composition, are less than 5% by weight, preferably less than 2% by weight, more preferably less than 1% by weight .-%, even more preferably less than 0.5 wt .-% and in particular 0 wt .-% perfume oils.

The compositions of the present invention may be formulated neutral or mildly acidic. A preferred embodiment of the present invention are cosmetic or pharmaceutical body deodorizing compositions having a pH of between 5 and 8, preferably between 5.2 and 7.5, more preferably between 5 and 5 , 5 and 7.2 and especially between 5.6 and 7.0.

Another preferred embodiment of the present invention are cosmetic or pharmaceutical compositions suitable for body deodorization which have a pH between 2 and 7, preferably between 2.25 and 6.75, more preferably between 2.5 and 6.5, and especially between 3.0 and 6.0.

Preferably, the cosmetic or pharmaceutical body deodorizing compositions of the invention have an isotonic electrolyte content.

The term isotonic or isotonic (Greek same voltage or same pressure) in the context of the present invention in a broader sense, a solution with the same osmotic pressure as a comparison medium, for. As human sweat, in the narrower sense, a solution with the same osmotic pressure as the human blood, so with an osmolarity of 308 mosmol / l.

A further subject matter of the present application is a non-therapeutic, cosmetic method for regulating body odor, in particular for reducing body odor, in which a cosmetic or pharmaceutical composition according to the invention suitable for body deodorization is applied topically in an effective amount to the skin, in particular to the skin in the armpit area, is applied.

With regard to further preferred embodiments of the method according to the invention, what has been said about the compositions according to the invention applies mutatis mutandis.

QUOTES INCLUDE IN THE DESCRIPTION

This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Cited patent literature

• WO 2009/101615 A1 [0006]
• US 3887692 [0029]
• US 3904741 [0029]
• US 4359456 [0029]
• GB 2048229 [0029, 0031]
• GB 1347950 [0029]
• US 4775528 [0031]
• US 6010688 [0031, 0033]
• US 5643558 [0033]
• US 6245325 [0033, 0035, 0036, 0037, 0038]
• US 2571030 [0033]
• US 4017599 [0034]
• US 6042816 [0035, 0036, 0037, 0038]
• US 6902723 [0042, 0043, 0044, 0045]
• US 6074632 [0046, 0047]
• BE 825146 [0048]
• US 6663854 [0049]
• US 20040009133 [0049]
• US 7105691 [0071]
• US 6436381 [0072]
• US 6649152 [0072]
• US 6923952 [0074]
• GB 2299506 A [0075]
• US 6936242 [0131]
• WO 00/67712 A1 [0131]
• US 6838032 [0131]
• DE 19756454 A1 [0158]

Claims (35)

Cosmetic or pharmaceutical composition suitable for body deodorization, comprising in a cosmetically or dermatologically acceptable carrier a) at least one deodorant or antiperspirant active ingredient, b) at least one member of the group of bacteriophages active against at least one of the following: b1) Staphylococcus aureus b2) Staphylococcus hominis b3) Corynebacterium tuberculostearicum b4) Anaerococcus octavius. b5) Staphylococcus. lugdunensis b6) Finegoldia magna b7) Corynebacterium amycolatum b8) Corynebacterium afermentans b9) Staphylococcus epidermidis b10) Staphylococcus capitis b11) Staphylococcus haemolyticus b12) Propionibacterium avidum b13) Corynebacterium kroppenstedtii b14) Peptinophilus spec. Cosmetic or pharmaceutical body deodorizing composition according to claim 1, characterized in that the member (s) selected from the group of bacteriophages is / are selected from the group of lysogenic bacteriophages. Cosmetic or pharmaceutical body deodorizing composition according to claim 1, characterized in that the member (s) selected from the group of bacteriophages is selected from the group of lytic bacteriophages. Cosmetic or pharmaceutical body deodorizing composition according to any one of Claims 1 to 3, characterized in that it contains exclusively lytic bacteriophages active against Staphylococcus aureus. Cosmetic or pharmaceutical body deodorizing composition according to any one of Claims 1 to 3, characterized in that it contains exclusively lytic bacteriophages active against Staphylococcus hominis. Cosmetic or pharmaceutical composition suitable for body deodorization according to one of Claims 1 to 3, characterized in that it contains exclusively lytic bacteriophages active against Corynebacterium tuberculostearicum. Cosmetic or pharmaceutical composition suitable for body deodorization according to one of Claims 1 to 3, characterized in that it contains exclusively lytic bacteriophages active against anaerococcus octavius. Cosmetic or pharmaceutical body deodorizing composition according to any one of claims 1 to 3, characterized in that it contains exclusively lytic, anti-Staphylococcus. Lugdunensis contains effective bacteriophages Cosmetic or pharmaceutical composition suitable for body deodorization according to one of Claims 1 to 3, characterized in that it contains exclusively lytic, Finegoldia magna-active bacteriophages Cosmetic or pharmaceutical body deodorizing composition according to any one of Claims 1 to 3, characterized in that it contains exclusively lytic bacteriophages active against Corynebacterium amycolatum Cosmetic or pharmaceutical composition suitable for body deodorization according to one of Claims 1 to 3, characterized in that it contains exclusively lytic bacteriophages effective against Corynebacterium afermentans Cosmetic or pharmaceutical body deodorizing composition according to any one of Claims 1 to 3, characterized in that it contains exclusively lytic bacteriophages active against Staphylococcus epidermidis Cosmetic or pharmaceutical body deodorizing composition according to any one of Claims 1 to 3, characterized in that it contains exclusively lytic bacteriophages active against Staphylococcus capitis Cosmetic or pharmaceutical body deodorizing composition according to any one of Claims 1 to 3, characterized in that it contains exclusively lytic bacteriophages active against Staphylococcus haemolyticus Cosmetic or pharmaceutical body deodorizing composition according to any one of claims 1 to 3, characterized in that it contains exclusively lytic bacteriophages effective against Propionibacterium avidum Cosmetic or pharmaceutical body deodorizing composition according to any one of Claims 1 to 3, characterized in that it contains exclusively lytic bacteriophages active against Corynebacterium kroppenstedtii Cosmetic or pharmaceutical composition suitable for body deodorization according to one of Claims 1 to 3, characterized in that it contains exclusively lytic, against Peptinophilus spec. contains effective bacteriophages. Cosmetic or pharmaceutical composition suitable for body deodorization according to one of Claims 1 to 17, characterized in that it contains 10 ¹ -10 ^9, preferably 10 ² to 10 ⁸ , more preferably 10 ³ to 10 ⁷ , more preferably 10 ⁴ to 10 ^6, % by weight. %, and in particular 10 ⁴ to 10 ⁵ bacteriophages. Cosmetic or pharmaceutical body deodorizing composition according to any one of Claims 1 to 18, characterized in that it comprises at least one antiperspirant active in a total amount of 1-25% by weight, preferably 5-22% by weight and in particular 10% -20 wt .-%, based on the total weight of the active substance in the total composition. Cosmetic or pharmaceutical body deodorizing composition according to any one of Claims 1 to 19, characterized in that it contains 3-25% by weight, preferably 5-22% by weight and in particular 10-20% by weight of acidic aluminum and or aluminum / zirconium salts. Cosmetic or pharmaceutical body deodorizing composition according to one of Claims 1 to 20, characterized in that it contains 3-25% by weight, preferably 5-22% by weight and in particular 10-20% by weight of activated aluminum chlorohydrate. Cosmetic or pharmaceutical body deodorizing composition according to any one of claims 1 to 21, characterized in that it contains at least one passivating agent selected from the group consisting of phyllosilicates and / or talc, preferred passivating agents being selected from the group of clay minerals, in particular selected from montmorillonite , Nontronite, hectorite, saponite, sauconite, beidellite, allevardite, illite, halloysite, attapulgite and / or sepiolite. Cosmetic or pharmaceutical body deodorizing composition according to any one of claims 1 to 22, characterized in that it contains disteardimonium hectorite as a passivating agent. Cosmetic or pharmaceutical composition suitable for body deodorization according to one of Claims 1 to 23, characterized in that it contains 0.05-10% by weight, preferably 0.2-7% by weight, based on the weight of the ready-to-use composition. , more preferably 0.3-5% by weight and most preferably 0.4-2.5% by weight of deodorant active ingredients in the overall composition. Cosmetic or pharmaceutical body deodorizing composition according to Claim 24, characterized in that it contains less than 5% by weight, preferably less than 2% by weight, more preferably less than 1% by weight, even more preferably less than 0 , 5 wt .-% and in particular 0 wt .-% antiperspirant active ingredient (s). Cosmetic or pharmaceutical body deodorizing composition according to any one of claims 1 to 25, characterized in that it comprises a cosmetically or dermatologically acceptable carrier which can be used as a powder, in stick form, as aerosol spray, pump spray, liquid or gel roll on application, Cream, lotion, suspension, solution, gel or applied to a substrate. Cosmetic or pharmaceutical body deodorizing composition according to any one of claims 1 to 26, characterized in that it contains, based on the weight of the ready-to-use composition, 5-60% by weight, preferably 7.5-45% by weight preferably 10-40 wt .-% and most preferably 15-35 wt .-% ethanol and / or isopropanol. Cosmetic or pharmaceutical body deodorizing composition according to any one of Claims 1 to 26, characterized in that it contains less than 5% by weight, preferably less than 2% by weight, more preferably less than 1% by weight preferably contains less than 0.5 wt .-% and in particular 0 wt .-% ethanol and / or isopropanol. Cosmetic or pharmaceutical composition suitable for body deodorization according to one of Claims 1 to 28, characterized in that it contains 1-30% by weight, preferably 2.5-27.5% by weight, based on the weight of the ready-to-use composition. , particularly preferably 5-25 wt .-% and most preferably 5-20 wt .-% fatty alcohol (s) and / or PEG ethers of fatty alcohols and / or PPG ethers of fatty alcohols. Cosmetic or pharmaceutical body deodorizing composition according to any one of claims 1 to 29, characterized characterized in that it has a pH of between 5 and 8, preferably between 5.2 and 7.5, more preferably between 5.5 and 7.2 and in particular between 5.6 and 7.0. Cosmetic or pharmaceutical body deodorizing composition according to any one of claims 1 to 29, characterized in that it has a pH between 2 and 7, preferably between 2.25 and 6.75, more preferably between 2.5 and 6.5 and especially between 3.0 and 6.0. Cosmetic or pharmaceutical composition suitable for body deodorization according to one of Claims 1 to 31, characterized in that it contains from 0.05 to 5% by weight, preferably from 0.1 to 3% by weight, based on the weight of the ready-to-use composition. and in particular 0.25 to 2 wt .-% perfume oils. Cosmetic or pharmaceutical body deodorizing composition according to any one of Claims 1 to 31, characterized in that it contains, by weight of the ready-to-use composition, less than 5% by weight, preferably less than 2% by weight, more preferably less as 1 wt .-%, even more preferably less than 0.5 wt .-% and in particular 0 wt .-% perfume oils. Cosmetic or pharmaceutical body deodorizing composition according to any one of claims 1 to 33, characterized in that it has an isotonic electrolyte content. A method for regulating body odor, in particular for reducing body odor, wherein a cosmetic or pharmaceutical composition suitable for body deodorization according to one of claims 1 to 34 is applied topically in an effective amount to the skin, in particular to the skin in the underarm area.